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ABSTRACT 
 
 This project describes the design and synthesis of new compounds that are capable of 
targeting cells that express the estrogen receptor and producing cytotoxic N3-methyladenine 
DNA adducts in those cells.  These compounds contain a reactive methylsulfonate group 
connected to a unit that binds to DNA in the minor groove at adenine-thymine rich regions, and 
therefore, selectively methylates adenines in these regions at the N3 position.  This component is 
connected by a linking unit to estradiol, which binds to the estrogen receptor, and therefore, is 
expected to selectively target these compounds to cells that express the estrogen receptor.  The 
linking unit is the only variable component in the design, and can be altered in order to optimize 
the DNA and estrogen receptor binding properties of the compound, and to modulate the water 
solubility of the compounds.  The synthesis of three compounds varying in linker length by one, 
two, and three methylene units is described. 
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 DNA in all cells is subject to many chemical alterations.  Some agents that damage DNA 
include ultraviolet light, oxygen radicals produced during normal cellular respiration, chemicals 
in the environment (poly aromatic hydrocarbons), and drugs used for chemotherapy.1 If the 
genetic information encoded in the DNA is to remain uncorrupted, any chemical changes that 
occur must be corrected.  A failure to repair DNA can produce cell death and/or mutations.2 Cell 
death resulting from DNA-damage is put to beneficial use in the treatment of diseases like 
cancer. 
 The hallmark of all cancers is continuous cell division.3 Each cell division requires both 
the replication of DNA and the transcription and translation of many genes needed for continued 
growth.    Many drugs used for cancer therapy function by targeting the rapidly dividing cancer 
cells and damaging their DNA.3 Certain classes of anti cancer drugs that specifically target DNA 
such as, melphalan, bizelesin and cyclophosphamide, which are DNA alkylating agents.4 These 
drugs damage the DNA of both normal and cancerous cells.  Normal cells upon DNA-damage go 
into cell-cycle arrest, and repair enzymes are triggered, which are able to repair the damage 
before the cell can progress to cell division.  This DNA-damage is not repaired in cancerous cells 
before cell division starts because these rapidly- dividing cells do not enter cell cycle arrest, and 
also because the repair systems are not usually functioning well in these cells.  When replication 
of damaged (unrepaired) DNA starts in these cancer cells during cell division, recognition of the 
damage triggers a cascade of events resulting in the death of the cell.  
Since the cytotoxicity of these alkylating drugs results from the existence of damaged 
DNA during cell division, many other cell types that are also proliferating rapidly, such as the 
cells of the intestinal lining, bone marrow and hair follicles are also destroyed, because their 
DNA repair enzymes are unable to repair the damage before initiation of cell division.  This 
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undesired damage in these normal cells is what results in many of the unpleasant side effects of 
chemotherapy such as gastric irritation, fatigue and hair loss.3  
A more disturbing aspect of chemotherapy with DNA alkylating drugs is that it poses a 
significant risk of causing a new or secondary cancer (often leukemia) that is a direct result of 
the extensive DNA-damage caused by the drugs used to treat the initial or primary cancer.  This 
secondary cancer is often untreatable with the drugs that were used to treat the primary cancer. 
 These undesired side-effects of cancer chemotherapy can be minimized or eliminated by 
using drugs that damage DNA in a particular manner, such that it causes only cell death and does 
not result in mutations, and by making this drug specific to the targeted cell.  For example, when 
DNA-methylation occurs at the N3 position of adenine, cytotoxic non-mutagenic N3-
methyladenine adducts are formed.  This specific DNA-damage can be caused by Me-Lex 
(Figure 1.1) a compound that has been shown to methylate the N3 position of adenines in the 
minor groove of DNA at A/T rich regions. Over 95% of the DNA-adducts formed by Me-Lex is 
N3-methyladenine.  Additionally, the DNA-damage caused by Me-Lex has been shown to be 
exclusively cytotoxic and non-mutagenic. Therefore, if Me-lex could be targeted to specific 
cells, it may be possible to achieve cell-selective cytotoxicity. 
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Figure 1.1: Structure of Me-Lex 
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There are many examples of targeting ligands used to send chemical agents to specific 
cells.  One example is glucoseamine, which is a naturally occurring ligand that is selectively 
transported into the pancreatic β-cells that produce insulin via the Glut-2 transporter.5  
 Estradiol is another ligand that has been used for targeting specific cell types, in 
particular, cells that express the estrogen receptor (ER), like early stage breast cancer cells.  
Other alkylating agents have been selectively targeted to ER positive cells by tethering them to 
estradiol.23 
 This thesis describes the synthetic methodology used to make novel compounds that 
combined the ability of estradiol to target cell that express the ER, with the ability of Me-Lex to 
produce cytotoxic N3-methyladenine adducts.  Such new compounds can be used to test the 
hypothesis that N3 methyl adenine adducts can be generated in specific cells by tethering Me-
Lex to a ligand that specifically targets those cells. 
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2.1. Background: 
 
 The research described in this thesis involves the development of an efficient synthetic 
methodology for making new compounds that are capable of delivering cytotoxic damage to 
DNA in estrogen receptor positive cells.  The strategy that was employed to design these 
compounds was to chemically combine a compound that binds selectively in a sequence specific 
manner and forms exclusively cytotoxic adducts with a compound that targets estrogen receptors 
using suitable linkers.  In order to be successful in the design (and synthesis) of such compounds, 
it is necessary to understand the structural features of the compounds that influence site and 
sequence specific DNA binding and methylation, and those that affect binding to the ER.  An 
understanding of these factors will influence the site and modes of connection of the two 
functional units of the desired target compounds. 
 
2.1.1. DNA Structure: 
DNA (deoxyribose nucleic acid) is a double-stranded molecule twisted into a double 
helix.  Each strand is comprised of a sugar-phosphate backbone and attached bases, which is 
connected to a complementary strand by non-covalent hydrogen bonding between the paired 
bases. The bases are adenine (A), thymine (T), cytosine (C) and guanine (G), where A and T are 
paired together by two hydrogen bonds and G and C are paired together by three hydrogen 
bonds.  The twisting of the double helix results in the DNA having two distinct grooves, the 
major and minor grooves (Figure 2.1).  The major groove is shallow and wide and this is where 
many proteins and enzymes interact with DNA.  The minor groove is the deep and narrower 
groove. 
 16
 
Figure 2.1: DNA base pairing (A with T and G with C), and the major and minor grooves 
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Figure 2.2 illustrates a top view of DNA if it were sliced perpendicular to the axis of the 
helix at the A/T and G/C base pairs, and also shows the hydrogen bonding between each of the 
base pairs which bring the two strands together forming the major and minor grooves.  As a 
result, certain sites on the base pairs face the major groove and others face the minor groove.  
Sites in the major groove are more easily accessible and include the O4 of thymine, the N7 and 
N6 of adenine, N7 of guanine, N4 of cytosine, and the O6 of guanine.  The sites that lie in the 
minor groove are more difficult to access and include the O2 of thymine, the N3 of adenine, the 
O2 of cytosine and the N2 and N3 of guanine. 
 
2.1.2. Reactivity of DNA Towards Alkylating Agents: 
  Numerous nucleophilic sites on DNA are susceptible to alkylation by alkylating agents, 
these sites are indicted by arrows in Figure 2.2.  The extent of alkylation is a function of 
accessibility and nucleophilicity of the particular site.  The sites on the G/C base pair, in the 
major groove, that are susceptible to alkylation include the N4 of cytosine, the O6 of guanine and 
the N7 of guanine.  In fact, the N7 of guanine is the site on DNA most commonly alkylated since 
it is highly nucleophilic and most easily accessible, by alkylating agents.  The G/C base pair also 
includes sites in the minor groove that are vulnerable to alkylation, examples of these are the O2 
of cytosine, and the N2 and N3 of guanine. Since these sites lie within the minor groove, and are 
consequently less accessible, they are less commonly alkylated as compared to the N7 of 
guanine.  On the A/T base pair the sites susceptible to alkylation include the O4 of thymine, and 
the N7 and N6 of adenine in the major groove and the O2 of thymine and N3 position of adenine.  
In addition, the phosphate on the backbone of DNA can also be alkylated. 
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Figure 2.2: Structure and pairing of DNA bases indicating major and minor groove sites. 
        Each arrow indicates a site which can be alkylated. 
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2.1.3. Biological Consequences of DNA Methylation: 
Methylation of DNA can result in different biological consequences depending on what 
site has been methylated.  The N7 position of guanine in the major groove is the most commonly 
methylated site on DNA.  Methylation at this site appears to have no biological outcome and 
leads to neither cytotoxic nor mutangenic consequences.7-10 The O6 site, which too lies in the 
major groove, and is also involved in the base-pairing hydrogen bonding interactions, is another 
site that is commonly methylated by methylating agents.  Formation of O6-methylguanine 
adducts is known to lead to both mutations and cell-toxicity. 7-11  
Methylation at other sites such as the N2 of guanine, the O2 and O4 of thymine and O2 of 
cytosine has been implicated in mutagenicity.7-11 Methylation at the N3 site of adenine, which 
lies in the minor groove, has been shown to result in cytotoxicity, but does not lead to 
mutations.7, 9,11-14 Thus, compounds that can generate exclusively N3-methyladenine adducts can 
be used to destroy cells without any risk of mutagenicity.  
 
2.1.4. Structure and Properties of Me-Lex: 
Me-Lex (shown in Figure 2.3) is a neutral compound that exclusively produces N3-
methyladenine adducts in the minor groove of DNA at A/T rich regions. These N3-
methyladenine adducts produced by Me-Lex have been shown to be highly cytotoxic and non-
mutagenic.   
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Me-Lex has a natural crescent shape, which enables it to fit well in the minor groove of 
DNA (Figure 2.4).  It binds at A/T rich regions due to the favorable hydrogen bonding and Van 
der Waals interactions between the pyrrole units of Me-Lex and adenine thymine base pair 
(Figure 2.5, a, b).  Me-lex does not bind to guanines because of the unfavorable steric 
interactions between the pyrrole units of Me-lex and the exocyclic amine present on guanine 
(Figure 2.5 c).  When Me-Lex binds to the minor groove of DNA at A/T rich regions, it reacts 
with the most nucleophilic site in those regions, which is the N3 position of adenine.  Once the 
methyl group is transferred to the adenine, the resultant sulfonate anion leaves the DNA due to 
electrostatic repulsion from the poly anionic DNA backbone.15 
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Figure 2.4: Molecular model illustrating Me-lex bound within the minor groove of DNA. 
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Figure 2.5: a.) Interaction of Me-Lex at A-T rich regions of DNA, in the minor 
                                groove, resulting in methylation of N3-adenine sites 
   b.) Favorable H-bonding and van der Waals interactions between     
        adenine and the pyrrole amide units of Me-Lex, which result in its 
        selective binding at A/T rich regions. 
            c.) Unfavorable steric conflicts between guanine and the pyrrole amide 
                    units of Me-Lex preventing it from binding to the minor groove of  
        DNA at G/C regions. 
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2.1.5. Structure and Properties of the Estrogen Receptor and its Naturally Occurring Ligand, β-
Estradiol: 
 The ER is a member of the nuclear hormone receptor family found in the cytoplasm of 
cells.16, 22 It functions as a ligand activated transcription regulator when it is bound with its 
natural ligand, estradiol.16 The ER is found in various tissues and cell types including the brain, 
bones, arteries and the human ovaries and breast cells.  The structure of the ER has a canonical 
alpha-helical sandwich shape that is made up of 12 alpha helices that are arranged into three anti-
parallel layers as shown in Figure 2.6.17,18 This arrangement allows for a large buried binding 
pocket where estradiol is sequestered after entering the receptor channel. The ER, when inactive, 
resides mainly in the nucleus of cells, to become activated it moves into the cytosol of the cell 
where it then binds estradiol.18 The binding of estradiol to the ER allows for a conformational 
change of the receptor that places a lid over the steroid binding pocket, exposing 
transcriptional residues that are necessary for DNA binding.17-20   
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Figure 2.6: Structure of the Human Estrogen Receptor, with Estradiol bound within the  
      hormone binding pockets.6 
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It has been shown that the ER is over-expressed in early stage breast cancer cells, which 
require estradiol for their continued growth.21, 22 Therefore, there are several reports in literature 
of therapeutic agents being attached to estradiol in order to selectively deliver them to breast 
cancer cells.  The site and mode of connection of agents to estradiol must be such that it does not 
interfere with the binding of estradiol to the ER, It has been shown, in literature that certain 
modifications at the 7α, 11α, 16α, and 17β sites (Figure 2.7) still allow estradiol to bind to the 
estrogen receptor, whereas modifications at other sites drastically diminish ER binding. 19, 23, 24 
Also, since estradiol binds within a long narrow channel of the ER, it is necessary that the tether 
used be long enough to extend out of this channel.  There is evidence to show that tethers have to 
be 6 carbons in length or longer to allow for estradiol to bind within the ER.  
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Figure 2.7:  Structure of estradiol.  The sites to which tethers can be attached, without  
     significantly interfering with estradiols binding to the ER, are 7α, 11α, 16α, 
     and 17β (indicated by arrows). 
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The compound shown in Figure 2.8 is an example in which a DNA alkylating nitrogen 
mustard has been attached to estradiol in order to selectively destroy breast cancer cells.  This 
compound was reported to be successfully transported to the nucleus of estrogen receptor 
positive cells, and resulted in alkylation at the N7 site of guanines.   
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Figure 2.8:  Structure of an alkylating compound (nitrogen mustard) attached to the 
       7α position of estradiol, which has been shown to alkylate DNA in ER- 
                  positive breast cancer cells. 
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2.2. Design: 
 The goal of this research was to synthesize compounds that can produce cytotoxic N3-
methyladenine adducts in ER-positive cells.  The molecules designed for the project are shown 
in Figure 2.9.  The estradiol and DNA-damaging components were connected by a linking unit, 
which is the only variable component in the design, and can be altered in order to optimize the 
DNA and estrogen receptor binding properties of the compound, and to modulate the water 
solubility of the compounds. 
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Figure 2.9: Design of molecules synthesized in this project. 
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2.3 Significance: 
 The successful preparation of the target compounds will enable us to test whether 
cytotoxic N3-methyladenine adducts can be selectively produced in ells that express the ER by 
using this strategy.  The success of the approach described here will also demonstrate the 
feasibility of using this strategy to target different kinds of cells that express a unique 
protein/receptor, ad generate cytotoxic, non-mutagenic, N3-methyladenine adducts in these cells 
by attaching Me-Lex to an appropriate ligand.  The ability to successfully target and generate 
only cytotoxic, non-mutagenic N3-methyladenine adducts in specific tumor cells can lead to the 
direct destruction of these cells while minimizing the common chemotherapy side-effects (such 
as hair loss and gastric irritation).  Since the specific DNA-damage caused by these new 
compounds do not cause mutations (mutations resulting from the extensive DNA-damage caused 
by common chemotherapy drugs are believed to be responsible for the occurrence of secondary 
cancers in patients who survive the primary cancer), such new drugs can also eliminate the 
incidence of secondary cancers that are reported for several chemotherapy drugs. 
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CHAPTER 3:  SYNTHESIS OF THE CELL TARGETING LIGAND 
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 Estradiol is being used as a cell-targeting ligand, which is to have Me-Lex attached at 
the 7α position to maintain sufficient binding to the ER.  This compound must be synthesized in 
such a way that it can easily be attached to Me-Lex.  The synthesis of this compound starts with 
commercially obtained β-estradiol.  Amine functionality is added to the end of the 6-carbon 
tether, this would make it possible to form an amide linkage between Me-Lex and estradiol.  
Therefore, the unit that was synthesized is shown in Figure 3.1.  The synthesis has been 
described in literature, with minor modifications.25-29 The outline of the procedures adopted is 
shown in Scheme 3.1. 
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Figure 3.1.  Structure of the cell-targeting segment that will be synthesized. 
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Scheme 3.1 
 The alkyl group was attached to the 7α position, however the 7α position was not 
reactive and it must first be made reactive by the conversion the 6-carbon into a ketone, which 
then rendered the 7α position acidic.  Base was then used to make the carbanion, followed by 
alkylation.  To prevent interference from the OH groups, they were first protected.  Details of the 
synthesis are described below. 
 The synthesis of 9 began with commercially obtained β-estradiol, where the 2 OH 
groups were protected using dihydropyran (Scheme 3.2) as described in literature.25-29 This 
reaction of protecting the OH groups proceeded well, however since the site of reaction produced 
chiral centers, different stereoisomers were formed.  In this case 4 diasteromers were produced 
due to the two chiral centers indicated by an (*) in Scheme 3.2.  This lead to a complicated NMR 
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spectrum, however, the formation of the isomers was of no consequence because these protecting 
groups were removed later in the synthesis. 
OH
HO O
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Pyridinium p-toluenesulfonate
(catalyst)
CH2Cl2
85%
O
O
*
*
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Scheme 3.2 
Compound 1 was isolated as a viscous oil upon removal of the solvent.  However, 
complete removal was not achieved even under high vacuum for prolonged time.  Therefore, 
determination of the quantity was difficult because part of it was solvent.  This made calculations 
in the subsequent step more difficult due to the fact that the calculations would not be accurate 
considering solvent was still present.  However, the product could be crystallized using a 9:1 
EtOH/H2O mixture.  To obtain the compound as a white solid, it was first slowly heated in a 
warm water bath to 50°C for 30 minutes and cooled slowly to precipitate the product.  All 
previous reports described compound 1 as a viscous oil.25 This time, compound 1 was isolated as 
a powdery white solid in an 85% yield. 
 The next step of the synthesis was the introduction of an alcoholic group in the 6-postion 
to form 2 followed by the conversion of the alcohol to a ketone to form 3 (Scheme 3.3).  The 
addition of the alcohol was achieved using potassium tert butoxide, diisopropylamine and n-
BuLi to produce the lithium salt.  This was followed by the addition of trimethylborate to trap the 
compound as a borate salt. Compound 2 was obtained as a white foamy solid in a 74% yield.  
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Compound 2 was formed as two stereoisomers; no further attempt was made to separate the 
isomers because the alcohol was subsequently oxidized into the ketone. 
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Scheme 3.3 
 The introduction of the ketone rendered the hydrogen in the 7α position acidic.  This 
conversion involved the oxidation of the benzylic alcohol 3 into a ketone.  The oxidation was 
accomplished using TEMPO (2,2,6,6-Tetramethylpiperidine 1-oxy) 25 as a catalyst and was 
achieved in a reasonable yield of 78% as a yellow foamy solid.  Good yields were obtained for 
this reaction when the temperature was held lower between 0-5°C.  Higher temperatures above 
5°C resulted in lower yields, while temperatures any cooler than 0°C drastically slowed the 
reaction. 
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After the synthesis of the ketone the 7α-position could be alkylated with 6-iodohexene, 
which was synthesized from 5-hexen-1-ol (Scheme 3.4).  5-Hexen-1-ol was dissolved in a 
mixture of diethyl ether/acetonitrile, and triphenylphosphine, imidazole, and iodine was added.  
This product was purified by column chromatography using hexanes as the elutant, but removal 
was difficult due the product being volatile.  Therefore, it could not be placed under high 
vacuum.  Because of this, the product was used in excess to account for the presence of some 
remaining solvent.  
 
OH I
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diethyl ether/acetonitrille
1) triphenylphosphine
imidazole
2) Iodine
 
Scheme 3.4 
 Once the alkylating agent, 6-iodohexene, was synthesized it was then reacted with 3.  
Introduction of the alkyl group at the 7α position of estradiol was achieved first by generating the 
enolate with potassium tertbutoxide, then trapping the enolate with triethyl borate.  This 
prevented O-alkylation and also ensured that the 6-iodohexene was added to the 7α position and 
not the 7β position.  This was then followed by the addition of 6-iodohexene.  This resulted in 
the introduction of the alkyl group at the α-position, (Scheme 3.5) in a 43% yield.  No attempt 
was made to verify the addition at the 7α position, however all reports indicate that the addition 
of the alkyl group was present at the 7α position, and the NMR spectra is an exact match to the 
NMR of the reported compounds.25-27 
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Scheme 3.5 
After the addition of the alkyl group to the 7α position, the deprotection of the 3-phenolic 
and 17-hydroxyl OH groups was done, followed by the reduction of the ketone (Scheme 3.6).  
The process of reducing the ketone ultimately resulted in the deprotection of the OH groups.  
Published reports indicate that it was necessary to first deprotect the OH groups before reducing 
the ketone to avoid low yields.28 Therefore, removing the protecting groups first, followed by the 
reduction of the ketone resulted in higher yields, which resulted in obtaining compound 5 as a 
foamy white solid in an 81% yield. 
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Scheme 3.6 
Once the ketone was reduced, the OH groups were reprotected using TBSCl.  This 
protecting group affords only 1 isomer, making the interpretation of NMR relatively simple.  
This is illustrated in Scheme 3.7 below. TBSCl was activated by imidazole to form a complex 
that is then reacted with 5, which resulted in the reprotected compound 6 in a 78% yield. 
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Scheme 3.7 
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 Once the alcoholic groups were reprotected, the terminal alkene was converted to 
the alcohol via anti-markovnikov addition of water across a double bond using 9-BBN 
(9-borabicyclo[3.3.1]nonane), KOH, and hydrogen peroxide to form the alcohol 7 as a 
white solid in a 72% yield (Scheme 3.8). 
O
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O
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6 7
1. 9-BBN
2. KOH, H2O2
THF
72%
Si
Si
Si
Si
 
Scheme 3.8 
This alcohol was converted to the amine (Scheme 3.9), by the addition of phthalamide by 
using Mitsunobo conditions and subsequently treating the phthalamide with hydrazine to form 
the amine in an 80% yield.   
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 The introduction of the hexyl amino was a laborious 9-step synthesis with an overall 
yield of 6%.  Because of this, some of the compound was obtained commercially from Quality 
Chemical Laboratories for subsequent reactions.  This compound 9 a or b could then be coupled 
with the DNA methylating unit that was suitably functionalized as a carboxylic acid. 
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CHAPTER 4:  SYNTHESIS OF THE DNA METHYLATING UNIT 
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 There are several key features of the target molecules.  The first is DNA recognition, 
which is achieved by the bis-pyrrole units.  The hydrogen bonding interactions with the minor 
groove is just the same as with Me-Lex.  The second is the reactive methyl group that will be 
transferred to the N3 position of adenine.  The reactive methyl sulfonate that transfers the methyl 
group was introduced late in the synthesis, in the very last step, because of its reactivity.  We 
were trying to make these compounds with linker variations that would be introduced at the C-
terminus of the molecule.  They were composed of (CH2)n, where n is either 1, 2, or 3.  These 
linkers are esters that were ultimately hydrolyzed to carboxylic acids, which allowed for the 
addition of 9, forming an amide linkage.   
 A synthesis was attempted that would allow for the easy addition of the linker at a later 
stage in the synthesis, this would be followed by the addition of the cell-targeting component, 
then functionalized to the reactive methyl sulfonate, this is illustrated in Figure 4.1 
 
 
 
 
 
 
 
 
 
 46
 
Figure 4.1: Attempted strategy to prepare compounds to target ER positive cells, and  
                             methylate N3-adenine in those cells. 
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 The synthesis used for the DNA-recognition unit was done following published 
procedures, with some modifications.13, 30 The overall strategy adopted for the synthesis of the 
minor groove recognition unit is such that it could be easily combined with the cell-targeting unit 
estradiol, and also so the reactive methyl sulfonate would be added last in the overall synthesis.  
The synthesis of 9 was expensive in time and resources, so it was desirable to minimize the 
number of manipulations after the addition of 9.  Which means it was necessary to functionalize 
the bis-pyrrole unit as much as possible before the addition of 9.  The first attempt was to 
synthesize the compound shown below in Figure 4.2.   
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Figure 4.2: Bis-pyrrole unit to allow for the easy addition of linkers at a later stage of the 
                         Synthesis. 
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All attempts to hydrolyze the ester without affecting the alkene were unsuccessful.  This is due to 
the aromatic ester requiring harsher conditions for hydrolysis.  This complication made it 
necessary to add the linkers earlier, so the synthesis adopted is shown below in Scheme 4.1.  This 
modification was of no consequence considering the addition of the linkers and the steps 
thereafter were produced in high yields.   
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Scheme 4.1 
 
The synthesis of the DNA recognizing dipyrrole unit, 22 started with the 
trichloroacetylation of N-methyl pyrrole.  Compound 11 was synthesized following scheme 4.2 
by reacting trichloroacetyl chloride with N-methyl pyrrole, this afforded compound 11 in a 93 % 
yield. 
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 Compound 11 was nitrated using fuming nitric acid as the nitrating reagent (Scheme 4.3).  
Upon nitration, the formation of the desired 4-nitro product, along with a small amount of the 
undesired 5-nitro isomer was obtained.  When complete, the addition of water precipitated the 
product, which has a lower solubility due to the hydrolysis of the acetic anhydride to acetic acid. 
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Scheme 4.3 
It was found that by stirring the precipitate with hexane overnight eliminated all of the undesired 
isomer.  It was then possible to obtain 12 as a pure isomer in good yields (80%).   
Compound 12 is stable to aqueous hydrolysis.  Usually, trichloro acetyl groups are very 
reactive with nucleophiles.  With this compound, the electronic configuration is just right so that 
water is too weak of a nucleophile to react, making 12 stable to aqueous hydrolysis.  However, 
amines are stronger nucleophiles, displacing chloroform as a by-product, which was then easily 
removed by rotary evaporation. 
At this stage of the synthesis, various linking units were attached.  They were obtained as 
an amino ester, which was commercially available.  The three linkers chosen are shown in 
Scheme 4.4, where R = CH2, CH2CH2, or CH2CH2CH2.  These amines were stirred with 12 at 
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room temperature in EtOAc, which resulted in the formation of the product, without the 
necessity of dry conditions.  CCl3 is eliminated as CHCl3 and aqueous HCl eliminated any 
unreacted amine, since the linkers were used in excess to ensure the complete reaction of 12.  
These compounds were obtained in yields greater than 80%. These compounds now contain the 
component to be attached to 9.  
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 The nitro group in compound 15 was reduced with H2 gas under pressure in the presence 
of Pd/C catalyst and subsequently reacted with another unit of 12 to give the bis-pyrrole unit 20 
(Scheme 4.5) in yields greater than 70%. 
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Initially compound 15 was reduced and not characterized.  The amine produced is 
aromatic, so the reaction with 12 took several days.  Low yields were obtained due to 
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decomposition and air oxidation of the amine.  To overcome this problem, producing the amine 
salt in the hydrogenator could minimize the decomposition.  To test this, HCl was added directly 
to the hydrogenator during the reduction of the 15.  The HCl salt of the amine was formed, but 
the ester was also hydrolyzed (Scheme 4.6).  To avoid acid hydrolysis of the ester, the HCl was 
added to the parr jar after the complete reduction of the amine, which formed only the HCl salt 
of the amine leaving the ester intact.    The free amine could then be formed in situ by the slow 
addition of TEA, which resulted in yields greater than 70% for compound 20.   
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Scheme 4.6 
 
 These nitro bis-pyrrole compounds were reduced under high pressure hydrogenation, 
then subsequently reacted with acroloyl chloride to produce the olefins (Scheme 4.7).  In this 
reaction, DIEA was used as the scavenger of the HCl that was formed upon the reaction of the 
amine and the acryloyl chloride.  The reaction was performed at low temperatures and protected 
from light to prevent polymerization.  Compound 21 was produced in high yields (>85%). 
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Scheme 4.7 
The hydrolysis of the ethyl ester 21 produced the carboxylic acid that could then be 
condensed with compound 9.  Initially, the hydrolysis was performed as reported in the 
literature, by first dissolving the compound in ethanol, adding the NaOH dissolved in H2O and 
reacting under reflux.  Performing the reaction in this manner hydrolyzed the ester but also 
resulted in the addition of an OH across a double bond via Michael addition, the proposed 
product is shown in Figure 4.3.   
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Figure 4.3: Proposed Michael Addition product from the base hydrolysis of the 
                           Ester. 
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The reaction was then performed at room temperature and methanol was used instead of 
ethanol as the solvent.  If HCl was added with methanol present, the carboxylic acid was 
esterified to the methyl ester by trans-esterification as indicated by NMR.  When the reaction 
was carried out in the polar aprotic solvent acetone, the addition of HCl did not give rise to 
complications, which resulted in high yields for compound 22 (Scheme 4.8).   
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Using base in acetone produced the enolate of acetone, which may have resulted in side 
products, derived from acetone, being formed.  However, they were easily washed away with a 
50/50 hexane/ether mixture, in which the desired products are not soluble. 
Compound 22 was synthesized from N-methyl pyrrole with overall yields greater than 
30%.  These compounds can now be condensed with 9 to form the bifunctional molecule that has 
the ability to bind to the A/T rich regions of the minor groove of DNA and to be specific to ER 
positive cells.    
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The DNA sequence recognition compound capable of recognizing A/T rich regions in the 
minor groove of DNA and the cell-targeting component capable of binding to the ER, have been 
obtained as compounds 22 and 9 and are shown in Figure 5.1a) and b).  The DNA recognizing 
unit 22 is present as an acroloyl imide that has to be derivatized as the methyl sulfonate capable 
of methylating the N3 position of adenine.  The other terminus is a carboxylic acid, which was 
combined with the amine of 9 to form an amide linkage.  The cell-targeting compound 9 is 
estradiol, with a 6-carbon tether functionalized as an amine at the 7α position, and the OH groups 
protected.  Occasionally with the synthesis of 9, the protecting group of the 17-hydroxyl OH was 
removed as shown in Figure 5.1b, however it was found that both 9a and 9b participated equally 
in subsequent reactions, therefore 9b was not reprotected to 9a. 
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Figure 5.1:  a) DNA sequence recognizing compound 22 functionalized as a carboxylic 
                            acid 
       b) Cell-targeting compound 9 synthesized with variance in 17-hydroxyl OH  
               protection. 
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5.1: Combination of the two functional units and derivitazation to final desired  
        compounds: 
 Scheme 5.1 below outlines the proposed synthesis for the assembling the functional units 
22 and 9 and derivatizing further to the reactive methyl sulfonate.  These compounds contained 
both the DNA recognition and cell-targeting units.  The carboxylic acid of 22 and the amine of 9 
were first coupled, followed by the conversion of the alkene to the sulfonic acid, which also 
resulted in the removal of the protecting groups on estradiol.  Finally, the reactive methyl group 
could be introduced to the molecule.   
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Scheme 5.1 
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 The condensation of 22 and 9 was achieved using EDCI and HOBT as coupling agents.  
Initial reactions using these reagents resulted in low yields of the products.  The mechanism of 
how these reagents function is shown in Figure 5.2.  EDCI is a water-soluble carbodiimide that 
first reacted with the carboxylic acid, which was then immediately trapped by HOBT forming 
the O-acylisourea intermediate.  This intermediate was then able to react with the desired amine, 
which formed the product and regenerated HOBT.  Typically, HOBT reacts quickly to form the 
O-acylisourea, but, it is possible for EDCI to form an unreactive N-acylurea intermediate before 
HOBT is able to form the desired intermediate.39 It has been reported that CuCl2 and DMAP 
lowered the incidence of the undesired N-acylurea intermediate and increased product yields.39, 40 
Compound 23 was obtained in yields greater than 70% using this mixture of reagents, (Scheme 
5.2). 
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Figure 5.2.  Mechanism by which EDCI and HOBT form an amide bond. 
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Scheme 5.2 
The next step was the conversion of the alkene to the sulfonic acid (Scheme 5.3).  This 
reaction was accomplished by using NaOH and NaHSO3 under reflux as described in literature.44 
The acidification using HCl during the workup of the reaction resulted in the protonation of the 
sulfonate salt to form the sulfonic acid, as well as the removal of the protecting groups present on 
estradiol.  Compound 24 was obtained in yields greater than 70%.   
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Scheme 5.3 
The proposed mechanism for the addition of the sulfonic acid is shown below in Figure 
5.3.  This reaction proceeds via Michael addition, where the sulfur of sodium bisulfite (NaHSO3) 
acted as the Michael donor, and the alkene of 23 acted as the Michael acceptor.  The reaction 
was initiated by the addition of base, which acted as a catalyst removing the hydrogen from 
sodium bisulfite.  This formed an intermediate that subsequently reacted with the alkene to form 
the desired Michael product that existed in equilibrium between the enol and the ketone, favoring 
the ketone tautomer.4 
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Figure 5.3.  The mechanism for the Michael addition of sodium bisulfite across 
                                  an alkene.  
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5.2:  Attempted Methylation of the Sulfonic Acids: 
The final step of the synthesis was the conversion of the sulfonic acid 24 to the methyl 
sulfonate.  There are several methylating agents available to methylate sulfonic acids.  The agent 
used to methylate Me-lex is 3-methyl-p-tolyltriazene; this is a methylating agent that requires an 
acidic hydrogen for methylation.  Figure 5.4 illustrates the mechanism where the acidic hydrogen 
of the sulfonic acid first protonates 3-methyl-p-tolyltriazene, which then methylates the sulfonate 
ion, forming the desired methyl sulfonate, nitrogen gas, and p-toluidine as side products.  This 
reaction was carried out in dioxane under reflux conditions for 5 hours.13, 30  
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Figure 5.4:  Mechanism for the methylation of a sulfonic acid using 3-methyl-p- 
                           tolyltriazene. 
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3-Methyl-p-tolyltriazene is an effective methylating agent for sulfonic acids, but it must 
react such that methylation does not occur on the 3-phenolic and 17-hydroxyl OH of estradiol.  
To test that these groups of estradiol will not get methylated, estradiol was reacted under the 
conditions mentioned above (Scheme 5.4).  No methylation of the OH groups was observed, 
indicating that this would be a suitable reagent for the methylation of compound 24. 
OH
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N
NHN
H3C
3-methyl-p-tolyltriazine
dioxane, 55 oC
5 hours
NO REACTION
 
Scheme 5.4 
However, methylation of compound 24b was not achieved with the above reaction 
conditions.  No methylation was observed, which may be due to the compound not having 
suitable solubility in dioxane.  Therefore, the reaction was subjected to prolonged heating under 
reflux conditions, still with no methylation achieved.   
Alkylation with two other methylating agents was attempted. Trimethylorthoformate 
(TMOF) and trimethylorthoacetate (TMOA) have both been reported to convert sulfonic acids to 
methyl sulfonates, where the methylating agents act as both the solvent and reagent.31-33 
Compound 24b was taken up in these reagents separately.  While compound 24b was soluble in 
both, no methylation was observed, even under reflux conditions for 24 hours (Scheme 5.5).  
100% of starting material was recovered in both cases. 
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Scheme 5.5 
 Since the attempts to convert the sulfonic acid 24b using the reagents mentioned were 
unsuccessful, other reported literature showed that iodomethane has been used to convert silver 
salts of sulfonic acids to their respective methyl sulfonates.34 However, when attempted with 
compound 24b, the synthesis was also unsuccessful, presumably because of complications with 
solubility. 
 Other reagents and methods have to be attempted to convert these sulfonic acids to their 
respective methyl sulfonates.  For example, alternative solvents could be used for the reaction 
with 3-methyl-p-tolyltriazene.  Other methylating agents should also be explored, such as 
diazomethane, which is well known and very reactive. 
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When all three components are assembled, the DNA recognition unit, the cell-targeting 
unit, and the reactive methyl sulfonate, they can directly be tested for their ability to methylate 
the N3 position of adenine by reacting these compounds with genomic DNA and observing 
adducts formed.  Also, these compounds can be tested in cells that express the ER compared to 
cells without the ER, for their toxicity.  If the compounds are not selectively cytotoxic for ER 
positive cells, there are several factors to account for.  The compounds may not be taken up into 
cell, due to inefficient binding of the compounds to the ER, or they are getting into the cell, but 
not binding to DNA to allow for methylation.  Also, the methyl group of these compounds might 
not be reactive which could be a result from the methyl group being hydrolyzed within the 
cytoplasm before reaching the DNA.  One has to verify that each of the individual components 
are functioning as envisioned.  To do this, the DNA-recognizing component must be assessed for 
its ability to bind to the A/T rich regions of the minor groove of DNA, separately from the cell-
targeting component, which must be assessed for its binding affinity to the ER.   
Crystal structures of compounds similar to the final compounds, but lacking the cell-
targeting component, have been developed, and computational studies on these compounds 
revealed their binding affinity to DNA.  Figure 6.1 illustrates the information gathered from 
similar computational studies that were performed on one of the target molecules, and have 
revealed that the bis-pyrrole compound 27a is capable of achieving binding at the A/T rich 
regions of the minor groove of DNA, without major steric interference from the cell-targeting 
component.  These computational studies can be further verified by using model compounds. 
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Figure 6.1:  Computational model of compound 27a bound into the minor groove of 
                              DNA 
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In order to test compounds for their binding, unreactive model compounds must be made.  
If the model compound were reactive, binding would be unable to be measured since a reaction 
would be taking place within the molecule.  Therefore, model compounds that lack the reactive 
methyl sulfonate must be used to determine first, if DNA methylation would occur within the 
minor groove of DNA at A/T rich regions when estradiol attached as the cell-targeting ligand, 
and second if estradiol would bind to the ER with the DNA recognition component attached.  
Figure 6.2 illustrates the one difference between the target methylating compounds and the 
unreactive model compounds, which is that the target molecules possess a reactive methyl 
sulfonate, and the model compounds contain an unreactive methyl sulfone.    
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Figure 6.2:  The unreactive model compound containing an unreactive methyl  
        sulfone, compared to the reactive DNA methylating compound, 
        containing a reactive methyl sulfonate. 
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The binding ability of these model compounds will be compared to the binding of known 
compounds.  For example, the binding of the model compounds to the A/T rich regions of the 
minor groove of DNA will be compared to the binding of the known compound Me-Lex, also, 
the model compounds will be tested for their binding affinity for the ER, which will be compared 
to the binding affinity of unmodified estradiol.  If these results are similar, it is likely that the 
target reactive molecules will behave in a similar fashion. 
The model compounds with varying lengths of R will be tested to see how this variation 
in the molecule will affect the binding to the minor groove of DNA, and to the ER.  The planned 
synthesis of these molecules is outlined in Scheme 6.1 below.  Compound 20 was first be 
coupled to 3-(methylsulfonyl) propanoic acid, which was previously synthesized from the 
oxidation of the methyl sulfide, forming an amide linkage.  The ester of 26 could be 
subsequently hydrolyzed and coupled at the amine terminus of 9 forming an amide bond.  This 
could then be followed by the deprotection of the OH groups, yielding the final model 
compounds. 
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The coupling of 3-(methylsulfonyl) propanoic acid to 20c was accomplished using EDCI 
and HOBT (Scheme 6.2), resulting in a 74% yield of 26.   
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Scheme 6.2 
Scheme 6.3 illustrates that when compound 26 was subjected to standard hydrolysis, 
none of the desired compound was formed; the entire product was obtained as compound 22c. 
The proposed mechanism of the removal of the methyl sulfone is illustrated in Figure 6.3 below, 
where base extracts the acidic hydrogen forming the double bond, and elimination of the methyl 
sulfonate.41-42 
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Figure 6.3:  Mechanism for the removal of the methyl sulfone during base hydrolysis 
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Therefore, the ester with the methyl sulfone, 26 cannot be used for the synthesis of the 
model compounds.  This pathway was abandoned and an alternate route was devised.  In Scheme 
6.4, a nitro bis-pyrrole unit containing a linker functionalized as a carboxylic acid would be 
condensed with 9 forming an amide linkage.  The coupling would be followed by first the 
reduction of the nitro to an amine, followed by the coupling of 3-(methylsulfonyl) propanoic acid 
to form another amide linkage.  The final step would be the removal of the OH protecting group 
with strong acid, yielding the final unreactive model compounds.  Once these compounds are 
synthesized they can be used to test their ability to bind to the minor groove of DNA and to the 
ER. 
 
 79
N
NH
O
H
N
N
NH
O O
N
H
HO
OH
S
O
O
O
H3C
R
N
H
N
O
HNN
O2N
O
R
O
OH
TBSO
OHH2N
N
NH
O
H
N
N
NO2
O
O
N
H
TBSO
OH
R O
S
O
O
H3C
OH
EDCI
HOBT
DMAP
CuCl2
HCl
9
28
1) Pd/C
H2
EtOH
2)EDCI
HOBT
DMAP
CuCl2
 
 
Scheme 6.4 
 The unexpected advantage of forming compound 22c during the hydrolysis of 26 implies 
that 28 could be synthesized and used directly as a model compound for binding studies, and as 
Scheme 6.5 illustrates, by using conditions for base hydrolysis, 28 could easily be converted to 
23, which would then be followed by the addition of the sulfonic acid to for 24 and finally, the 
compound could be methylated forming the reactive compound 25.  By using this method, time 
and resources could be saved. 
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7.1. General: 
 All solvents and reagents were purchased from VWR International (West Chester, 
Pennsylvania) or Sigma-Aldrich (Atlanta, Georgia) and were of the highest grade available 
unless otherwise noted.  Flash chromatography was performed with silica gel (230/400 mesh, 
Life Force Inc.).  TLC was performed on glass plates coated with silica gel (Whatman 
International, Maidstone, England, 150 A) that had a fluorescence indicator and were detected by 
UV visualization.  All rotary evaporations were carried out using a Buchi R-3000 or a Buchi R-
114 rotary evaporator equipped with a Brinkmann model B-16 vacuum aspirator.  
Hydrogenations were performed using a Parr Hydrogenation Apparatus in a 500 mL Parr jar.  
Melting points were determined using a Mel-Temp II. 
 All anhydrous reactions were carried out under positive pressure argon.  Glassware 
used for anhydrous reactions were dried overnight in an oven at 140 °C or dried over a flame, 
assembled while still hot, and cooled to room temperature under argon.  Solvents and reagents 
(liquids) for anhydrous reactions were obtained in bottles with sure-seal caps and transferred by 
using oven-dried needles and glass syringes. 
 All 1H-NMR and 13C-NMR spectra were recorded with a Bruker 400MHz NMR 
spectrometer, using deuterated DMSO or deuterated chloroform as the solvent.  The deuterated 
DMSO was obtained in sealed ampoules from Sigma-Aldrich.  The deuterated chloroform was 
obtained from Alfa Aesar.  The spectra are reported in ppm and referenced to deuterated DMSO 
(2.49 ppm for 1H, 39.5 ppm for 13C) or referenced to deuterated chloroform (7.26 ppm for 1H, 77 
ppm for 13C).  The samples were contained in 5 mm Pyrex glass NMR tubes obtained from 
Wilmad-LabGlass, Buena, New Jersey. 
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7.2. Synthesis: 
 (3,17β-Bis(2-tetrahydropyranyloxy)estra-1,3,5(10)triene) (1). To a solution of β-
estradiol (30 g, 110.2 mmol) in CH2Cl2 (375 mL) was added dihydropyran (101 mL) and then 
pyridinium ρ-toluenesulfonate (20 mg).  The reaction mixture was fitted prepared with a reflux 
condenser and was allowed to reflux for 3 hours while monitoring by TLC.  The solvent was 
then removed by rotary evaporation to yield clear oil.  Ethanol was added to the clear oil, the 
flask was then spun in a warm water bath until the oil dissolved and a white precipitate formed.  
The flask was allowed to cool to room temperature upon which a white solid further fell out of 
solution, then the flask was placed into the refrigerator overnight, followed by placement in the 
freezer for another 24 hours, upon which a white solid precipitated.  The precipitate was filtered 
to yield 48.51 g (85%) of 1 as a white solid.  mp = 77-82°C, Rf = 0.43 (5:1, hexane/EtOAc), 1H 
NMR (CDCl3): Identical to that published in literature.25-27.  13C NMR (CDCl3): Identical to that 
published in literature.25-27 
  (3,17β-Bis(2-tetrahydropyranyloxy)estra-1,3,5(10)-triene-6-ol) (2).   To a cooled (-
78 °C) solution of 1 (18.5 g, 42 mmol) in THF (105 mL) was added 1.0 M potassium tert-
butoxide (KOt-Bu) in THF (85 mL), diisopropylamine (1.5 mL), and 1.6 M n-BuLi in hexanes 
(48 mL).  Upon addition of n-BuLi the reaction mixture turned dark red.  After 15 minutes 
trimethyl borate (11.3 mL) was added and the reaction mixture turned pale yellow.  After 5 
minutes 35% H2O2 (52 mL) was added to the reaction, and a white solid formed.  After stirring, 
the solid dissolved to yield a clear pale yellow liquid. The reaction mixture then stirred at room 
temperature for 1 hour.  The organic phase was partitioned between toluene and diluted with 
10% HCl.  The organic layer was dried over MgSO4 and filtered.  The solvent was removed by 
rotary evaporation and the product was purified by flash chromatography (2:1, hexane/EtOAc) to 
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give 14.3 g (74%) of 2 as a white solid. mp = 74-79°C, Rf  =0.32 (2:1, hexane/EtOAc), 1H NMR 
(CDCl3): Identical to that published in literature.25-27.  13C NMR (CDCl3): Identical to that 
published in literature.25-27 
  (3,17β-Bis(2-tetrahydropyranyloxy)estra-1,3,5(10)-triene-6-one) (3).  To a cooled 
(0-5 °C) solution of 2 (12 g, 26.3 mmol) in CH2Cl2 was added 2,2,6,6-Tetramethylpiperidine 1-
oxy (TEMPO) (0.220 g) and KBr (0.330 g in 11 mL of DI H2O).  14% Sodium hypochlorite (pH 
was adjusted to 8.5 by adding saturated NaHCO3) was added until a less polar compound was 
formed.  The organic phase was then washed with 10% sodium thiosulfate and deionized H2O.  
The organic layer was dried over MgSO4 and gravity filtered.  The solvent was removed by 
rotary evaporation and the product was then purified by flash chromatography (3:1, 
hexane/EtOAc) to give 9.3 g (78%) of 3 as a white solid. mp = 52-57°C, Rf  = 0.70 (3:1, 
hexane/EtOAc), 1H NMR (CDCl3): Identical to that published in literature.25-27.  13C NMR 
(CDCl3): Identical to that published in literature.25-27 
  (3,17β-Bis(2-tetrahydropyranyloxy)-7α-(5-hexen-1-yl)-estra-1,3,5(10)-triene-6-
one) (4).  To a solution of 3 (2.0 g, 4.40 mmol) in ethyl ether (21 mL) was added 1.0 M KOt-Bu 
in THF (4.8 mL).  After 10 minutes 1.0 M triethylborane (5.5 mL) was added and the reaction 
mixture was stirred for 1 hour.  6-iodohexene (1.1g) in ethyl ether was canulated into the reaction 
flask mixture.  After 30 minutes of stirring an equivalent amount of 1.0 M KOt-Bu in THF (4.8 
mL) was added and the reaction mixture was stirred overnight.  The reaction was then quenched 
with DI water and extracted with CH2Cl2.  The organic layer was dried over MgSO4 and gravity 
filtered.  The solvent was removed by rotary evaporation and the product was purified by flash 
chromatography (5.5:0.5, hexane/EtOAc) to give 1.02 g (43%) of 4 as a white solid.  mp = 39-
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46°C, Rf = 0.19 (5.5:0.5, hexane/EtOAc), 1H NMR (CDCl3): Identical to that published in 
literature.25-27.13C NMR (CDCl3): Identical to that published in literature.25-27 
 (6-iodo-1-hexene).  To a solution of 5-hexen-1-ol (3.0g, 30 mmol) in a mixture of 
diethyl ether/acetonitrile (145/37 ml) was added triphenylphosphine (15.8g) and imidazole 
(4.1g).  Iodine (15.3 g) was then added slowly to the reaction and the reaction was allowed to stir 
at room temperature until only one spot was observed by TLC.  Diethyl ether (100ml) was then 
added and the reaction mixture was then filtered through celite.  The filtrate was then washed 
with saturated sodium bicarbonate and saturated NaCl, followed by a water wash.  The organic 
layer was then dried over Mg SO4 and gravity filtered.  The solvent was then removed by rotary 
evaporation and the product was purified by flash chromatography (hexanes) to give 5.9 (94%) 
of 6-iodo-1-hexene as a clear liquid.  1H NMR (CDCl3): δ 1.51 (m, 2H), 1.84 (m, 2H), 2.08 (m, 
2H), 3.19, (t, 2H, J = 7 Hz), 4.99 (m, 2H), 5.78 (m, 1H). 
  (7α-(5-hexen-1-yl)-estra-1,3,5(10)-triene-3,17β-diol) (5).  To a cooled (0 °C) 
solution of 4 (0.550 g, 1.0 mmol) in MeOH (24 mL) was added acetyl chloride (2.4 mL) in 0.4 
mL aliquots.  The ice water bath was removed and the reaction was allowed to stir at room 
temperature for 30 minutes.  The solvent was removed by rotary evaporation to give a yellow oil.  
To a cooled (0 °C) solution of the crude oil in CH2Cl2 (12 mL) was added triethylsilane (12.1 
mL) and boron trifluoride diethyl etherate (38.5 mL).  The ice water bath was removed and the 
reaction solution was allowed to stir overnight.  20% K2CO3 (120 mL) was added resulting in a 
biphasic mixture. The biphasic mixture was then filtered through silica and to the filtrate was 
added CH2Cl2.   The organic layer was then dried over Mg SO4 and gravity filtered.  The solvent 
was then removed by rotary evaporation and the product was purified by flash chromatography 
(2:1, hexane/EtOAc) to give 0.286g (81%) of 5 as a white solid. mp = 108-113°C, Rf = 0.26 (2:1, 
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hexane/EtOAc), 1H NMR (CDCl3): Identical to that published in literature.25-27.  13C NMR 
(CDCl3): Identical to that published in literature.25-27 
  (3,17β-Bis(τ-butyldimethylsilanyloxy)-7α-(5-hexen-1-yl)-estra-1,3,5(10)-triene) 
(6).  To a cooled (0 °C) solution of imidazole (4.29 g) in DMF (22 mL) was added tertbutyl 
dimethylsilyl chloride  (4.27 g).  The reaction was then stirred for 30 minutes and then a solution 
of 5 (2.2 g, 6.2 mmol) in DMF (4 mL) was added all at once.  The reaction was then stirred 
overnight and then was hydrolyzed with 0.1% K2CO3.  The reaction mixture was then extracted 
with CH2Cl2 and washed with deionized H2O.  The organic layer was dried over MgSO4 and 
gravity filtered.  The product was then purified by flash chromatography (2:1, hexane/EtOAc) to 
give 2.8 g (78%) of 6 as an oil, which was converted to a white solid under high pressure 
vacuum.  mp =  54-57 °C, Rf = 0.82 ( 2:1, hexane/EtOAc), 1H NMR (CDCl3): Identical to that 
published in literature.25-27.  13C NMR (CDCl3): Identical to that published in literature.25-27 
  (3,17β-Bis(τ-butyldimethylsilanyloxy)-7α-(6-hydroxy-hexen-1-yl)-estra-1,3,5(10)-
triene) (7) .  To a solution of 6 (0.170 g, 0.292 mmol) in THF (10 mL) was added 0.5 M 9-
borabicyclo[3.3.1]nonane in THF (1.5mL).  The reaction was then stirred overnight and 
hydrolyzed with 3 M KOH (1.3 mL).  After 5 minutes 30% H2O2 (1.3 mL) was added and the 
reaction was stirred for 3 hours. Saturated NaHCO3 (12 mL) was added and then extracted with 
CH2Cl2.  The organic layer was dried over MgSO4 and gravity filtered.  The solvent was 
removed by rotary evaporation and the product was then purified by flash chromatography (20%, 
EtOAc/hexane) to give 0.128 g (74%) of 7 as a white solid. mp = 53-55°C, Rf = 0.58 (20%, 
EtOAc/hexane), 1H NMR (CDCl3): Identical to that published in literature.25-27.  13C NMR 
(CDCl3): Identical to that published in literature.25-27 
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  (3,17β-Bis(τ-butyldimethylsilanyloxy)-7α-(6-phthalimido-hexen-1-yl)-estra-
1,3,5(10)-triene) (8).  To a solution of triphenylphosphine (0.086 g) in THF (1.5 mL) was added 
diisopropyl azodicarboxylate (0.065 mL) dropwise.  The reaction was allowed to stir for 40 
minutes and a white precipitate formed.  The phthalimide (0.048 g) was then added followed by 
7 (0.100 g, 0.165 mmol).  The reaction was stirred at 0 °C for 1 hour and then at room 
temperature overnight.  The solvent was removed by rotary evaporation and the product was then 
purified by flash chromatography (5% hexane/EtOAc) to give 0.105 g (87%) of 8 as a yellow 
solid. mp = 55-58°C, Rf = 0.83 (5% hexane/EtOAc), 1H NMR (CDCl3): Identical to that 
published in literature.25-27.  13C NMR (CDCl3): Identical to that published in literature.25-27 
  (3,17β-Bis(τ-butyldimethylsilanyloxy)-7α-(6-phthalimido-hexen-1-yl)-estra-
1,3,5(10)-triene) (9a and 9b).  To a solution of 8 (0.084 g, 0.114 mmol) in ethyl ether/EtOH 
(1.11 mL/1.11 mL) was added anhydrous hydrazine (555 µL) at room temperature in one 
installment.  The reaction mixture was then prepared with a reflux condenser and refluxed for 2 
hours.  During this time a white solid formed on the walls and the solution turned a pale 
green/yellow.  5% NaOH was added after the reaction cooled to dissolve the white solid.  After 
30 minutes DI H2O was added and then was extracted with CH2Cl2.  The organic layer was dried 
over MgSO4 and gravity filtered.  The solvent was then removed to give 0.055 g (80%) of 9 as a 
white solid. mp = 69-72 °C, Rf = 0.67 (6:1 CHCl3/MeOH), 1H NMR (CDCl3): Identical to that 
published in literature.25-27.  13C NMR (CDCl3): Identical to that published in literature.25-27 
 3-Methoxy-17β-hydroxy-1, 3, 5(10)-estratriene (10).  β-estradiol (0.200 g, 0.734 mmol) 
and potassium carbonate (0.203 g, 1.47 mmol) were added to a 25 mL round bottom flask and 
dissolved in 7 mL of acetonitrile.  Iodomethane (0.91 mL, 1.47 mmol) was then added all at 
once.  The flask was then equipped with a reflux condenser and allowed to reflux overnight.  The 
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solution was concentrated by rotary evaporation until dry.  This solid was dissolved in 
dichloromethane ad extracted with 1M HCl (1 x 100 mL) and DI water (1 x 100mL).  The 
organic layers were dried over MgSO4.  The solution was concentrated by rotary evaporation.  
The was placed under vacuum until dry which yielded a white foam 10 (0.185 g, 89%): mp 49-
52 °C.  TLC (EtOAc) Rf = 0.74.  1H NMR data (CDCl3): δ 7.17  7.21 (m, 1H) 6.83 (d, 1H, J = 8 
Hz), 6.77 (d, 1H, J = 2 Hz), 3.78 (s, 3H), 3.72 (m, 1H) 2.82 (d, J = 4 Hz, 2H), 0.77 (s, 3H).  13C 
NMR data (CDCl3): δ 157.43, 138.300, 132.66, 126.36, 113.82, 111.48, 81.95, 55.23, 50.03, 
43.96, 43.28, 38.86, 36.72, 30.59, 29.83, 27.26, 26.34, 23.14, 11.08. 
 2,2,2-trichloro-1-(1-methyl-1H-Pyrrol-2-yl)ethanone (11).  Trichloro acetyl chloride 
(50 mL, 0.170 mol) was added to 250 mL of dry dichloromethane in a 1000 mL flask flushed 
with argon.  N-methyl pyrrole (42 mL, 0.569 mol) was then added to 100 mL of dry 
dichloromethane in a dropping funnel.  This N-methyl pyrrole mixture was added drop wise to 
the trichloro acetyl chloride and stirred overnight.  A solution of potassium carbonate (32 g in 
250mL of water) was then added to the empty dropping funnel and dropped into the reaction 
mixture over a period of 2 hours to quench the reaction.  This mixture was extracted with DI 
water (2 x 300 mL) and dichloromethane (1x 300 mL).  The organic layers were dried over 
MgSO4.  The solution was concentrated by rotary evaporation until dry.  This was placed under 
vacuum until dry, which yielded a dark brown solid 11 (93.1 g, 93%): mp 53-57 °C. TLC (1:1 
EtOAc/Hexane) Rf = 0.81.  1H NMR data: δ 7.44 (d, J = 3.6 Hz, 2H), 6.29 (t, J =3.4 Hz, 1H), 
3.93 (s, 3H).  13C NMR data: δ 172.30, 135.73, 124.17,. 121.17, 109.54, 96.56, 38.44.  
 2,2,2-trichloro-1-(1-methyl-4-nitro-1H-pyrrol-2-yl)ethanone (12).  Pyrrole 11 
(25.00 g, 0.11 mol) was dissolved in acetic anhydride (175 mL) in a 500 mL round bottom flask 
and cooled to -78 °C in a dry ice/acetone bath.  This temperature was maintained for 10 minutes 
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when fuming nitric acid (12.3 mL) was added drop wise, using a drop funne,l over a period of 45 
minutes with constant stirring, ensuring that the temperature did not warm above -40 °C.  This 
mixture stirred for one hour at -40 °C.  The solution was then allowed to warm to room 
temperature and stirred for an additional two hours.  The solution was then cooled in an ice bath 
and cold DI water (101 mL) was added slowly in installments over a period of 45 minutes.  This 
mixture was stirred overnight, during which a yellow precipitate formed and was filtered under 
vacuum and dried to give 12 (23.48 g, 80%): mp 114-121 °C.  TLC (1:1 EtOAc/Hexane) Rf = 
0.56.  1H NMR data: δ 8.56 (d, J = 1.73 Hz, 1H), 7.78 (d, J = 1.71 Hz, 1H), 3.98 (s, 3H).  13C 
NMR data: δ 1.73.30, 134.73, 133.09, 121.09, 116.82, 95.02, 79.44. 
 (5-carboxy-1-methyl-1H-pyrrol-3-yl)(hydroxy)oxoammonium (13).  The nitro 
pyrrole 12 (0.500 g, 0.0018 mol) was dissolved in ethanol (15 mL) in a 50 mL round bottom 
flask and a solution of NaOH (0.368 g, 5 eq.) in H2O (2 mL) was added.  This was allowed to 
reflux until the disappearance of 12 was indicated by TLC (EtOAc).  The solution was 
concentrated by rotary evaporation to remove the majority of the EtOH.  The aqueous solution 
was cooled in an ice bath and then acidified with concentrated HCl until the final pH was 
approximately 1 when a precipitate fell out of solution.  The mixture was allowed to cool in the 
freezer for one more hour and the dark yellow solid precipitate as filtered out and rinsed with 
ice-cold water and air-dried to give pure 13 (0.250 g, 82%):  mp 177-181 °C.  TLC (5:2 
CHCl3/MeOH) Rf = 0.38.  1H NMR data: δ 13.15 (s, 1H), 8.23 (d, J = 2.0 Hz , 1H), 7.26 (d, J = 
2.0 Hz , 1H), 3.92 (s, 1H).  13C NMR data: δ 204.39, 161.45, 134.47, 129.67, 124.26, 111.86, 
37.96. 
 [5-(ethoxycarbonyl)-1-methyl-1H-pyrrol-3-yl](hydroxy)oxoammonium (14).  
Absolute ethanol (250 mL) was added to a flask flushed with argon.  This flask was then placed 
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in an ice bath.  To the flask was added solid sodium (0.635g, 0.0276 mol) in small increments.  
Once all the sodium was dissolved, pyrrole 12 (5.00g, 0.0184 mol) was added to the reaction 
flask all at once.  The reaction proceeded overnight and was indicated complete by TLC (1:1 
EtOAc/Hexane) to give 14 (2.98 g, 80%):  mp 290-294 °C.  TLC (1:1 EtOAc/Hexane) Rf = 0.80.  
1H NMR data: δ 8.30 (s, 1H), 7.31 (s, 1H), 4.26 (q, J = 6.0, 1.2 Hz, 2H), 3.93 (s, 3H), 1.29 (t, J = 
6.0 Hz, 3H).  13C NMR data: δ 159.88, 134.59, 129.94, 123.35, 111.98, 61.06, 37.98, 14.53. 
 ethyl N-({4-[hydroxy(oxo)ammonio]-1-methyl-1H-pyrrol-2- yl}carbonyl)glycinate 
(15a).  EtOAc dried over sieves (100 mL) was added to a flask flushed with argon.  The nitro 
pyrrole 12 (5.00g, 19 mmol) was added to the reaction flask followed by glycine ethyl ester 
hydrochloride (2.58 g, 22 mmol). TEA (7.8 mL, 56 mmol) dissolved in EtOAc dried over sieves 
(20 mL) was added to a dropping funnel equipped to the reaction flask.  Argon was bubbled 
through this solution, and this mixture was added drop wise over a period of 15 hours under 
argon.  Once all of the TEA mixture was added the reaction was allowed to stir for an additional 
48 hours under argon.  The white precipitate formed was filtered off and the filtrate was 
extracted with 1M HCl (2 x 100 mL) and DI water (1x 100 mL).  The organic layers were dried 
over MgSO4.  The solution was concentrated by rotary evaporation until dry and was placed 
under vacuum until a yellow solid formed to give 15a (3.72 g, 83%): mp 96-99 °C.  TLC (1:1 
EtOAc/Hexane) Rf = 0.54. 1H NMR data: δ 8.89 (t, J= 1.2Hz, 1H), 8.16 (d, J = 2.4 Hz, 1H), 7.51 
(d, J = 1.6 Hz, 1H), 4.14 (q, J = 6.0, 1.2 Hz, 2H), 3.96 (d, J = 6.0 Hz, 2H), 3.92 (s, 3H), 1.21 (t, J 
= 7.0 Hz, 3H).  13C NMR data: δ 170.12, 160.71, 134.35, 128.61, 126.11, 108.32, 60.97, 41.15, 
37.87, 14.51. 
 Ethyl N-[(1-methyl-4-nitro-1H-pyrrol-2-yl)carbonyl]-β-alaninate (15b).  
Compound 15b was synthesized by a procedure similar to the one described above for 15a using 
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(5.00 g, 19 mmol) of 12 and (3.40 g, 22 mmol) of β-alanine ethyl ester hydrochloride to obtain 
15b (3.97g, 88%): mp 127-129 °C.  TLC (1:1 EtOAc/Hexane) Rf = 0.33.  1H NMR data: δ 8.49 
(t, J = 5.2 Hz, 1H), 8.12 (d, J = 2.0 Hz, 1H), 7.41 (d, J = 2.0 Hz, 1H), 4.01 (q, J = 6.8, 7.2 Hz, 
2H), 3.91 (s, 3H), 3.42 (q, J = 5.6, 2.1 Hz, 2H), 2.55 (t, J = 7.0 Hz, 2H), 1.18 (t, 6.8 Hz, 3H).  13C 
NMR data: δ 171.63, 160.34, 134.23, 128.32, 126.71, 107.86, 60.42, 37.78, 35.41, 34.11, 14.51. 
 Ethyl 4-{[(1-methyl-4-nitro-1H-pyrrol-2-yl)carbonyl]amino}butanoate (15c).  
Compound 17 was synthesized by a procedure similar to the one described above for 15a using 
(5.00 g, 19 mmol) of 12 and (3.71 g, 22 mmol) of aminobutyrate hydrochloride to obtain 15c 
(4.08 g, 81%): mp 54-58 °C.  TLC (1:1 EtOAc/Hexane) Rf = 0.25.  1H NMR data: δ 8.38 (t, 5.3 
Hz, 1H), 8.11 (d, J = 1.6 Hz, 1H), 7.43 (d, J = 2.0 Hz, 1H), 4.05 (q, J = 6.8, 7.2 Hz, 2H), 3.91 (s, 
3H), 3.22 (q, J = 6.0, 7.6 Hz, 2H), 2.35 (t, J = 7.4 Hz, 2H), 1.75 (p, 7.2, 7.1, 7.2 Hz, 2H), 1.18 (t, 
7.0 Hz, 3H).  13C NMR data: δ 173.05, 160.31, 134.24, 128.21, 126.91, 107.72, 60.21, 38.41, 
37.77, 31.46, 34.84, 14.54. 
 (5-{[(3-carboxypropyl)amino]carbonyl}-1-methyl-1H-pyrrol-3-
yl)(hydroxy)oxoammonium (16).   The nitro pyrrole 15c (0.730 g, 2.6 mmol) was dissolved in 
ethanol (15 mL) in a 50 mL round bottom flask and a solution of NaOH (0.515 g, 13 mmol) in 
H2O (2 mL) was added.  This was allowed to reflux until the disappearance of 15c was indicated 
by TLC (EtOAc).  The solution was concentrated by rotary evaporation to remove the majority 
of the EtOH.  The aqueous solution was cooled in an ice bath and then acidified with 
concentrated HCl until the final pH was approximately 1 when a precipitate fell out of solution.  
The mixture was allowed to cool in the freezer for one more hour and the yellow solid precipitate 
was filtered out and rinsed with ice-cold water and air-dried to give pure 16 (0.660 g, 98%): mp 
248-250 °C.  TLC (CHCl3/MeOH) Rf = 0.60.  1H NMR data: δ 8.45 (t, J = 5.3 Hz, 1H), 8.11 (d, J 
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= 2.0 Hz, 1H), 7.45 (d, 2.0 Hz), 3.91 (s, 3H), 3.22 (q, J = 6.0, 7.6 Hz, 2H), 2.35 (t, J = 7.4 Hz, 
2H), 1.75 (p, 7.2, 7.1, 7.2 Hz, 2H).  13C NMR data: δ 174.67, 160.31, 134.22, 128.21, 126.91, 
107.74, 38.51, 37.79, 31.56, 24.86. 
 Methyl 1-methyl-4-{[(1-methyl-4-nitro-1H-pyrrol-2-yl)carbonyl]amino}-1H-
pyrrole-2-carboxylate (17).  Argon was bubbled through 50 mL EtOAc containing 2.5 mL 
TEA.  Methyl 4-amino-1-methyl-1H-pyrrole-2-carboxylate, HCl (1.62 g, 0.0085 mol) was then 
added to the solution followed by the addition of the nitro compound 12 (2.34 g, 0.0085 mol) and 
the solution was allowed to stir under Ar for 24 hours.  The pale yellow solid that was formed 
was filtered out, washed with DI H2O, and dried under vacuum to yield the pale yellow solid 17 
(2.41 g, 92%): mp 232-237 °C.  TLC (2:1 EtOAc/Hexane) Rf = 0.34.  1H NMR data: δ 10.26 (s, 
1H), 8.18 (d, J = 1.4 Hz, 1H), 7.56 (d, J = 2.0 Hz, 1H), 7.46 (d, J = 2.0 Hz, 1H), 6.89 (d, J = 2.0 
Hz, 1H), 3.96 (s, 3H), 3.85 (s, 3H), 3.75 (s, 3H).  13C NMR data: δ 161.18, 157.39, 134.28, 
128.72, 126.57, 122.62, 121.29, 119.33, 108.78, 108.09, 51.46, 37.88, 36.69. 
 1-methyl-4-{[(1-methyl-4-nitro-1H-pyrrol-2-yl)carbonyl]amino}-1H-pyrrole-2-
carboxylic acid (18).  The nitro ester 17 (7.00 g, 23 mmol) was suspended in EtOH (115 mL), 
and a solution of NaOH (2.8 g, 3 eq.) in H2O (15 mL) was added.  This suspension was allowed 
to reflux until the disappearance of 17 was indicated by TLC (EtOAc).  The solution was 
concentrated by rotary evaporation to remove all the EtOH.  The aqueous solution was cooled in 
an ice bath and then acidified with concentrated HCl until the final pH was approximately 1, 
which is when a precipitate fell out of solution.  The mixture was allowed to cool in the 
refrigerator overnight, and the brown solid precipitate was filtered out and rinsed with ice-cold 
water and air dried to yield pure 18 (6.01g, 89%): mp 199-203 °C.  TLC (EtOAc) Rf = 0.54.  1H 
NMR data: δ 10.39 (s, 1H), 8.17 (d, J = 1.6 Hz, 1H), 7.66 (d, J = 1.6 Hz, 1H), 7.44 (d, J = 2.0 Hz, 
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1H), 6.90 (d, J = 1.6 Hz, 1H), 3.97 (s, 3H), 3.84 (s, 3H).  13C NMR data: δ 162.31, 157.39, 
134.29, 128.64, 126.65, 122.40, 120.88, 120.32, 108.93, 108.23, 37.89, 36.63. 
 [5-({[5-(ethoxycarbonyl)-1-methyl-1H-pyrrol-3-yl]amino}carbonyl)-1-methyl-1H-
pyrrol-3-yl](hydroxy)oxoammonium (19).  The nitro pyrrole ester 14 (2.0 g, 0.010 mol) was 
dissolved in ethanol (30 mL) in a 500 mL parr jar and Pd/C (0.500 g) was added to it.  The 
mixture was shaken in a hydrogenator under pressurized hydrogen (75 psi) until the reaction was 
complete as indicated by TLC (EtOAc in 6 hours.).  The mixture was then acidified with 
concentrated HCl (1 mL).  The Pd/C was filtered out through celite, and the filtrate was 
concentrated by rotary evaporation and kept under vacuum overnight to yield yellow solid.  
Ethyl acetate dried over sieves (20 mL) was added to this solid in a 250 mL round bottom flask 
and the nitro pyrrole 12 (2.74 g, 0.010 mol) was added to the mixture.  TEA (4.2 mL, 0.030 mol) 
dissolved in EtOAc (5 mL) was then added drop wise using a dropping funnel.  This was allowed 
to stir for 48 hours during which time a yellow solid fell out of solution.  After the reaction was 
complete, as indicated by the disappearance of the starting material by TLC (EtOAc), the yellow 
solid was vacuum filtered to yield pure 19 (2.2g, 68%): mp 163-167 °C.  TLC (1:1 
EtOAc/Hexane) Rf = 0.58.  1H NMR data: δ 10.57 (s, 1H), 8.18 (d, J = 1.6 Hz, 1H), 7.75 (d, J = 
2.0 Hz, 1H), 7.46 (d, J = 2.0 Hz, 1H), 7.01 (d, J = 1.6 Hz, 1H), 4.22 (q, J = 6.6, 7.0 Hz, 2H), 3.96 
(s, 3H), 3.85 (s, 3H), 1.3 (t, J = 7.0 Hz, 3H).  13C NMR data: 157.44, 134.29, 128.67, 126.57, 
122.72, 121.25, 119.50, 109.02, 108.45, 59.87, 45.72, 37.93, 36.66, 14.74. 
 ethyl N-({4-[({4-[hydroxy(oxo)ammonio]-1-methyl-1H-pyrrol-2-
yl}carbonyl)amino]-1-methyl-1H-pyrrol-2-yl}carbonyl)glycinate (20a). Compound 20a was 
synthesized following a procedure similar to the one described above for 19 using 3.17g (0.012 
mol) of pyrrole 15a and 3.26 g (0.012 mol) of 12 to give 20a (3.4 g, 73%): mp 170-172 °C.  TLC 
 94
(1:1 EtOAc/Hexane) Rf = 0.28.  1H NMR data: 10.29 (s, 1H), 8.48 (t, J = 1.8 Hz, 1H), 8.18 (d, J 
= 2.0 Hz, 1H), 7.59 (d, J = 1.6 Hz, 1H), 7.28 (d, J = 2.0 Hz, 1H), 6.93 (d, J = 2.0 Hz, 1H), 4.14 
(q, J = 6.8, 7.2 Hz, 2H), 3.98 (s, 3H), 3.91 (d, J = 2.0 Hz, 2H), 3.82 (s, 3H), 1.21 (t, 6.8, 7.2 Hz, 
3H).  13C NMR data: δ 170.65, 161.84, 157.36, 134.24, 128.70, 126.72, 122.79, 121.97, 119.06, 
108.07, 104.95, 60.82, 41.15, 37.94, 36.60, 14.58. 
 Ethyl N-[(1-methyl-4-{[(1-methyl-4-nitro-1H-pyrrol-2-yl)carbonyl]amino}-1H-
pyrrol-2-yl)carbonyl]-β-alaninate (20b).  Compound 20b was synthesized following a 
procedure similar to the one described above for 20a using 4.0 g (0.015 mol) of pyrrole 15b and 
3.60 g (0.015 mol) of 12 to give 20b (4.73 g, 81%): mp 199-202 °C.  TLC (EtOAc) Rf = 0.64.  
1H NMR data: δ 10.26 (s, 1H), 8.18 (d, J = 1.2 Hz, 1H), 8.06, (t, J = 5.6 Hz, 1H), 7.59 (d, J = 1.2 
Hz, 1H), 7.23 (d, J = 1.6 Hz, 1H), 6.85 (d, J = 1.2 Hz, 1H), 4.10 (q, J = 6.8, 7.2 Hz, 2H), 3.96 (s, 
3H), 3.82 (s, 3H), 3.42 (q, J = 7.2, 6.8 Hz, 2H), 2.56 (t,  J = 7.0 Hz, 2H), 1.21 (t, J = 7.2 Hz, 3H).  
13C NMR data: δ 204.39, 171.83, 161.63, 157.30, 134.23, 128.66, 126.73, 123.41, 121.83, 
118.56, 60.35, 37.93, 36.49, 35.28, 34.45, 14.53. 
 Ethyl 4-{[(1-methyl-4-{[(1-methyl-4-nitro-1H-pyrrol-2-yl)carbonyl]amino}-1H-
pyrrol-2-yl)carbonyl}amino}butanoate (20c).  Compound 20c was synthesized following a 
procedure similar to the one described above for 20a using 4.0 g (0.014 mol) of pyrrole 15c and 
3.8g (0.014 mol) of 12 to give 20c (4.01 g, 71 %): mp 139-144 °C.  TLC (EtOAc) Rf = 0.69.  1H 
NMR data: δ 10.25 (s, 1H), 8.17 (d, J = 1.6 Hz, 1H), 8.09 (t, 1.8 Hz, 1H), 7.58 (d, J = 2.0 Hz, 
1H), 7.21 (d, J = 1.6 Hz, 1H), 6.86 (d, J = 1.4 Hz, 1H), 4.07 (q, J = 6.4, 7.2 Hz, 2H), 3.95 (s, 3H), 
3.81 (s, 3H), 3.20 (t, J = 1.8 Hz, 2H), 2.32 (t, J = 7.4 Hz, 2H), 1.76 (p, J = 6.8, 7.6, 7.2 Hz, 2H), 
1.19 (t, J = 7.0 Hz, 3H).  13C NMR data: δ 173.18, 161.64, 157.30, 134.23, 128.67, 126.75, 
123.61, 121.78, 118.44, 107.99, 104.48, 60.22, 38.17, 37.93, 36.48, 31.49, 25.14, 14.56. 
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 ethyl N-{[4-({[4-(acryloylamino)-1-methyl-1H-pyrrol-2-yl]carbonyl}amino)-1-
methyl-1H-pyrrol-2-yl]carbonyl}glycinate (21a).  Compound 20a (2.0 g, 5.2 mmol) was 
dissolved in 15 mL absolute ethanol and 250 mg Pd/C was added in a Parr jar.  The mixture was 
shaken under pressurized hydrogen (75 psi) until 20a had disappeared as indicated by TLC 
(EtOAc).  The Pd/C was filtered through celite, and the solution was rotary evaporated and the 
residue was kept under vacuum overnight.  The flask containing the residue was flushed with Ar 
and the residue was dissolved in anhydrous THF (60 mL) and DIEA (2.02 mL, 12.2 mmol) was 
added.  The solution was bubbled with argon and cooled to -40°C.  Acryloyl chloride (0.421 mL, 
5.2 mmol) was then added to the cooled solution drop wise.  The reaction temperature was 
regulated between 40°C to 20 °C and protected from light.  The reaction continued until it was 
complete, as indicated by TLC (6:1, CHCl3: MeOH).  The solution was concentrated by rotary 
evaporation re-dissolved in EtOAc and extracted with DI water (2x 250 mL).  The organic layers 
were dried over MgSO4.  The solution was concentrated by rotary evaporation until dry.  This 
was placed under vacuum to yield the product as yellow foam 21a (1.78 g, 86 %): mp 100-
105°C.  TLC (6:1 CHCl3/MeOH) Rf = 0.70.  1H NMR data: δ 10.12 (s, 1H), 9.95 (s, 1H), 8.42 (t, 
J = 5.5 Hz, 1H), 7.26 (d, J = 2.0 Hz, 1H), 7.25 (d, J = 2.0 Hz, 1H), 6.92 (d, J = 2.0 Hz, 1H), 6.91 
(d, J = 1.6 Hz, 1H), 6.37 (m, 1H), 6.19 (dd, J = 2.0, 16.8 Hz, 1H), 5.67 (dd, J = 2.0, 8.0 Hz, 1H), 
4.12 (q, J = 6.8, 7.2 Hz, 2H), 3.88 (d, J = 6.0 Hz, 2H), 3.83 (s, 3H), 3.78 (s, 3H), 1.21 (t, J = 6.8 
Hz, 3H).  13C NMR data: δ 170.68, 162.09, 161.93,158.79, 131.95, 123.44, 122.64, 122.52, 
122.15, 118.92, 105.12, 104.48, 60.80, 41.14, 36.63, 36.51, 14.59. 
 ethyl N-{[4-({[4-(acryloylamino)-1-methyl-1H-pyrrol-2-yl]carbonyl}amino)-1-
methyl-1H-pyrrol-2-yl]carbonyl}-β-alaninate (21b).  Compound 21b was synthesized 
following a procedure similar to the one described above for 21a using 2.0 g (5.03 mmol) of 20b, 
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0.407 mL (5.03 mmol) of acryloyl chloride and 1.88 mL (11.73 mmol) of DIEA to yield 21b as a 
yellow foam (1.85 g, 89 %): mp 87-92 °C.  TLC (6:1 CHCl3/MeOH) Rf = 0.69.  1H NMR data: δ 
10.11 (s, 1H), 9.91 (s, 1H), 8.06 (t, J = 5.2, 5.6 Hz, 1H), 7.27 (d, J = 1.6 Hz, 1H), 7.19 (d, J = 2.0 
Hz, 1H), 6.91 (d, J = 1.6 Hz, 1H), 6.84 (d, J = 1.6 Hz, 1H), 6.41 (m, 1H), 6.21 (dd, J = 2.0, 14.8 
Hz, 1H), 5.68 (dd, J = 2.0, 8.0 Hz, 1H), 4.07 (q,  J = 6.8, 7.2, 7.2 Hz, 2H), 3.84 (s, 3H), 3.79 (s, 
3H), 3.42 (q, J = 6.2, 7.2, 6.8 Hz, 2H), 2.52 (t,  J = 6.8, 7.2 Hz, 2H), 1.20 (t, J = 6.8, 7.2 Hz, 3H).  
13C NMR data: δ173.46, 172.32, 171.85, 162.10, 161.72, 158.75, 131.96, 126.02, 123.46, 
123.17, 123.12, 122.49, 122.15, 118.90, 118.42, 104.72, 104.44, 36.64, 35.26, 34.27. 
 ethyl 4-({[4-({[4-(acryloylamino)-1-methyl-1H-pyrrol-2-yl]carbonyl}amino)-1-
methyl-1H-pyrrol-2-yl]carbonyl}amino)butanoate (21c).  Compound 21c was synthesized 
following a procedure similar to the one described above for 21a using 2.0 g (4.9 mmol) of 20a, 
0.396 mL (4.9 mmol) of acryloyl chloride and 1.9 mL (11.33 mmol) of DIEA to yield 21c as a 
yellow foam (1.81 g, 87 %): mp 71-77 °C.  TLC (6:1 CHCl3/MeOH) Rf = 0.68.  1H NMR data: δ 
10.11 (s, 1H), 9.98 (s, 1H), 8.03 (t, J = 5.3 Hz, 1H), 7.26 (d, J = 2.0 Hz, 1H), 7.17 (d, J = 1.6 Hz, 
1H), 6.91 (d, J = 2.0 Hz, 1H), 6.85 (d, J = 1.6 Hz, 1H), 6.35 (m, 1H), 6.19 (dd, J = 2.4, 17.2 Hz, 
1H), 5.67 (dd, J = 2.0, 8.0 Hz, 1H), 4.05 (q, J = 7.2, 6.8 Hz, 2H), 3.83 (s, 3H), 3.78 (s, 3H), 3.17 
(t, J = 1.8 Hz, 2H), 2.31 (t, J = 7.0 Hz, 2H), 1.72 (p, J = 6.8, 7.6, 7.2 Hz, 2H), 1.18 (t, J = 7.0 Hz, 
3H).  13C NMR data: δ 173.18, 162.08, 161.74, 158.74, 131.95, 126.05, 123.47, 123.33, 122.45, 
122.14, 118.89, 118.31, 104.63, 104.40, 60.22, 38.16, 36.65, 36.42, 31.50, 25.17, 14.58. 
 N-{[4-({[4-(acryloylamino)-1-methyl-1H-pyrrol-2-yl]carbonyl}amino)-1-methyl-1H-
pyrrol-2-yl]carbonyl}glycine (22a).  Compound 21a (0.300 g, 0.747 mmol) was dissolved in 
acetone (4 mL).  NaOH (0.120 g, 2.99 mmol) was dissolved in 1 mL of DI H2O and added all at 
once to the reaction flask.  After 6 hours no starting material was left as indicated by TLC (6:1 
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CHCl3:MeOH).  To the reaction flask was added concentrated HCl until a pH of 1.  This material 
was stirred for 10 min. during which time a salt fell out of solution.  The solvents were then 
evaporated, followed by the addition of cold DI (1 mL) to the reaction flask.  Additional 
impurities were removed by stirring overnight in 50/50 mix of hexane/ether (50 mL/50 mL) to 
yield a yellow powder 22a, which was obtained by vacuum filtration (0.231 g, 85%): mp 130-
133 °C.  TLC (5:2 CHCl3/MeOH) Rf = 0.31.  1H NMR data: δ 10.15 (s, 1H), 9.96 (s, 1H), 8.45 
(t, J = 5.3 Hz, 1H), 7.28 (d, J = 2.0 Hz, 1H), 7.26 (d, J = 1.6 Hz, 1H), 6.94 (d, J = 2.2 Hz, 1H), 
6.92 (d, J = 2.0 Hz, 1H), 6.42 (m, 1H), 6.21 (dd, J = 2.0, 16.8 Hz, 1H), 5.68 (dd, J = 2.2, 10.8 Hz, 
1H), 3.92 (d, J = 6.0 Hz, 2H), 3.85 (s, 3H), 3.80 (s, 3H).  13C NMR data: δ 172.15, 171.19, 
162.12, 158.80, 131.95, 126.05, 123.44, 122.65, 122.46, 122.15, 118.94, 118.82, 105.19, 104.50, 
52.12, 41.03, 36.63 
 N-{[4-({[4-(acryloylamino)-1-methyl-1H-pyrrol-2-yl]carbonyl}amino)-1-methyl-1H-
pyrrol-2-yl]carbonyl}-β-alanine (22b).  Compound 22b was synthesized similar to the one 
described above for 22a using 0.500 g (1.2 mmol) of 21b, 6.42 mL of Acetone, 0.192 g (4.8 
mmol) NaOH, and 1.6 mL of DI water over a period of 30 min. to yield 22b as a yellow solid 
(0.410 g, 88%): mp 108-111 °C.   TLC (5:2 CHCl3/MeOH) Rf = 0.33.  1H NMR data: δ 10.15 (s, 
1H), 9.19 (s, 1H), 8.04 (t, J = 5.4 Hz, 1H), 7.27 (d, J = 1.2 Hz, 1H), 7.19 (d, J = 2.2 Hz, 1H), 6.92 
(d, J = 1.2 Hz, 1H), 6.84 (d, J = 2.0 Hz, 1H), 6.42 (m, 1H), 6.21 (dd, J = 2.0, 15.2 Hz, 1H), 5.68 
(dd, J = 2.0, 8.0 Hz, 1H), 3.84 (s, 3H), 3.80 (s, 3H), 3.38 (q, J = 6.2, 7.2Hz, 2H), 2.47(t,  J = 7.0 
Hz, 2H).  13C NMR data: δ 173.47, 162.10, 161.72, 158.75, 131.96, 126.03, 123.47, 123.17, 
122.48, 122.15, 118.90, 118.43, 104.72, 104.44, 36.64, 36.44, 35.31, 34.49. 
4-({[4-({[4-(acryloylamino)-1-methyl-1H-pyrrol-2-yl]carbonyl}amino)-1-methyl-1H-
pyrrol-2-yl]carbonyl}amino)butanoic acid (22c).  Compound 22c was synthesized similar to 
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the one described above for 22a using 0.400 g (0.932 mmol) of 21c, 4.98 mL of Acetone, 0.149 
g (3.7 mmol) NaOH, and 1.24 mL of DI water over a period of 90 minutes to yield 22c as a 
yellow solid (0.308 g, 82 %): mp 71-76 °C.  TLC (5:2 CHCl3/MeOH) Rf = 0.36.  1H NMR data: 
δ 10.24 (s, 1H), 9.93 (s, 1H), 8.05 (t, J = 5.5 Hz, 1H), 7.27 (d, J = 2.0 Hz, 1H), 7.18 (d, J = 1.6 
Hz, 1H), 6.93 (d, J = 1.6 Hz, 1H), 6.85 (d, J = 1.6 Hz, 1H), 6.44 (m, 1H), 6.18 (dd, J = 2.0, 14.8 
Hz, 1H), 5.65 (dd, J = 2.0, 8.0 Hz, 1H), 3.83 (s, 3H), 3.78 (s, 3H), 3.17 (t, J = 5.8 Hz, 2H), 2.25 
(p, J = 3.6, 3.5, 3.8 Hz, 2H), 1.71 (t, J = 7.0, 2H).  13C NMR data: δ 174.76, 162.09, 161.74, 
158.74, 131.96, 126.02, 123.47, 123.38, 122.44, 122.14, 118.89, 118.30, 104.62, 104.42, 38.27, 
36.64, 36.40, 31.61, 30.06, 25.21, 15.64. 
 4-(acryloylamino)-N-[5-({[2-({6-[(7ξ,8ξ,9ξ,14ξ,17ξ)-17-{[tert-
butyl(dimethyl)silyl]oxy}-3-hydroxyestra-1,3,5(10)-trien-7-yl]hexyl}amino)-2-
oxoethyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrole-2-carboxamide 
(23a).  In a flask flushed with argon, 22a (0.200 g, 0.536 mmol) was dissolved in 5 mL 
anhydrous DMF along with, EDCI (0.132 g, 1.5 eq.) DMAP (0.136 g, 2.5 eq.), HOBT (0.204 g, 
3 eq.), CuCl2 (0.006 g, 0.1 eq.).  After stirring for 30 min. the amine 9 (0.216 g, 0..446 mmol) 
was added and the solution was allowed to stir at room temperature over a period of two days 
until the disappearance of starting material as indicated by TLC (6:1 CHCl3/MeOH).  The 
solution was diluted with 100 mL DCM and the organic solution was extracted with H2O (2x, 
100mL), saturated NaHCO3 (2x, 150 mL), and 1 M HCl (2x, 150 mL).  The organic layer was 
then dried over MgSO4.  The resulting solution was rotary evaporated until dry to yield the 
product, 23a as dark yellow foam (0.278 g, 74 %): mp 152-158 °C.  TLC (6:1 CHCl3/MeOH) Rf 
= 0.64.  1H NMR data: δ 10.13 (s, 1H), 9.94 (s, 1H), 8.99 (s, 1H) 8.15 (t, J = 1.8 Hz, 1H), 7.77 (t, 
J = 1.8 Hz, 1H), 7.25 (d, J = 1.6 Hz, 1H), 7.22 (d, J = 2.0 Hz, 1H), 7.03 (d, J = 2.0 Hz, 1H), 6.91 
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(d, J = 1.6 Hz, 1H), 6.87 (d, J = 2.0 Hz, 1H), 6.49 (d, J = 2.0 Hz, 1H), 6.40 (s, 1H), 6.37 (m, 1H), 
6.18 (dd, J = 2.0, 15.2 Hz, 1H), 5.66 (dd, J = 2.0, 8.0 Hz, 1H), 3.83 (s, 3H), 3.78 (s, 3H). 13C 
NMR data: 169.43, 162.77, 162.09, 161.81, 158.77, 155.45, 136.44, 131.98, 129.96, 127.14, 
125.99, 123.45, 122.93, 122.58, 122.15, 118.89, 116.25, 113.32, 104.93, 104.49, 81.66, 45.86, 
43.71, 42.18, 38.96, 38.21, 36.64, 36.51, 36.25, 34.57, 33.21, 31.23, 30.98, 29.65, 28.05, 27.43, 
26.95, 26.21, 25.58, 22.48, 18.24, 11.80, -4.04. 
 4-(acryloylamino)-N-[5-({[3-({6-[(7ξ,8ξ,9ξ,14ξ,17ξ)-17-{[tert-
butyl(dimethyl)silyl]oxy}-3-hydroxyestra-1,3,5(10)-trien-7-yl]hexyl}amino)-3-
oxopropyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrole-2-carboxamide 
(23b).  Compound 23b was synthesized similar to the procedure described above for 23a using 
0.250 g (0.645 mmol) of 22b, 5 mL anhydrous DMF along with, EDCI (0.191 g, 1.5 eq.) DMAP 
(0.197 g, 2.5 eq.), HOBT (0.296 g, 3 eq.), CuCl2 (0.009 g, 0.1 eq.) and 0.314 g (0.645 mmol) of 
9 to yield 23b as yellow foam (0.421 g, 76 %): mp 139-144 °C.  TLC (6:1 CHCl3/MeOH) Rf = 
0.62.  1H NMR data: δ 10.10 (s, 1H), 9.89 (s, 1H), 8.97 (s, 1H), 7.98 (t, J = 1.8 Hz, 1H), 7.83 (t, J 
= 1.8 Hz, 1H), 7.26 (d, J = 2.0 Hz, 1H), 7.25 (d, J = 1.6 Hz, 1H), 7.18 (d, J = 1.6 Hz, 1H), 6.90 
(d, J = 2.0 Hz, 1H), 6.79 (d, J = 2.0 Hz, 1H), 6.49 (d, J = 2.2 Hz, 1H), 6.40 (s, 1H), 6.39 (m, 1H), 
6.19 (dd, J = 2.0, 15.2 Hz, 1H), 5.67 (dd, J = 2.0, 8.0 Hz, 1H), 3.82 (s, 3H), 3.78 (s, 3H).  13C 
NMR data: δ 170.70, 162.07, 161.64, 158.71, 155.42, 136.46, 131.95, 129.99, 127.15, 126.01, 
123.46, 123.23, 122.50, 122.14, 118.87, 118.36, 116.23, 113.30, 104.52, 104.41, 81.66, 45.87, 
43.70, 42.16, 38.86, 38.19, 37.21, 36.64, 36.43, 35.97, 33.18, 30.97, 29.65, 29.61, 28.01, 27.44, 
27.01, 26.21, 25.57, 22.77. 
 4-(acryloylamino)-N-[5-({[4-({6-[(7ξ,8ξ,9ξ,14ξ,17ξ)-17-{[tert-
butyl(dimethyl)silyl]oxy}-3-hydroxyestra-1,3,5(10)-trien-7-yl]hexyl}amino)-4-
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oxobutyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]-1-methyl-1H-pyrrole-2-carboxamide 
(23c).  Compound 23c was synthesized similar to the procedure described above for 23a using 
0.500 g (0.0012 mol) of 22c, 5 mL anhydrous DMF along with, EDCI (0.332 g, 1.5 eq.) DMAP 
(0.342 g, 2.5 eq.), HOBT (0.513 g, 3 eq.), CuCl2 (0.015 g, 0.1 eq.) and 0.504 g (0.645 mmol) of 
9 to yield 23c as yellow foam (0.421 g, 72 %): mp 122-126 °C.  TLC (6:1 CHCl3/MeOH) Rf = 
0.60.  1H NMR data: δ 10.10 (s, 1H), 9.88 (s, 1H), 8.97 (s, 1H), 8.10 (t, J = 1.8 Hz, 1H), 7.83 (t, J 
= 1.8 Hz, 1H), 7.25 (d, J = 1.2 Hz, 1H), 7.16 (d, J = 1.2 Hz, 1H), 7.08 (d, J = 1.6 Hz, 1H), 6.89 
(d, J = 1.2 Hz, 1H), 6.83 (d, J = 1.2 Hz, 1H), 6.49 (d, J = 2.2 Hz, 1H), 6.40 (s, 1H), 6.41 (m, 1H), 
6.23 (dd, J = 2.0, 15.2 Hz, 1H), 5.71 (dd, J = 2.0, 8.0 Hz, 1H), 3.81 (s, 3H), 3.77 (s, 3H).  13C 
NMR data: δ 172.08, 170.82, 162.77, 162.09, 161.69, 158.74, 155.44, 136.45, 131.97, 129.98, 
127.15, 126.02, 123.48, 123.40, 122.45, 122.15, 118.88, 118.28, 116.25, 113.32, 104.58, 104.43, 
81.67, 45.88, 43.71, 42.18, 38.88, 38.67, 38.20, 37.22, 36.64, 36.42, 36.25, 34.57, 33.56, 33.20, 
31.54, 31.23, 30.97, 29.64, 28.02, 27.44, 27.00, 26.22, 26.12. 
 3-{[5-({[5-({[2-({6-[(7ξ,8ξ,9ξ,14ξ,17ξ)-3,17-dihydroxyestra-1,3,5(10)-trien-7-
yl]hexyl}amino)-2-oxoethyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]amino}carbonyl)-1-
methyl-1H-pyrrol-3-yl]amino}-3-oxopropane-1-sulfonic acid (24a).  To a solution of alkene 
23a (0.240 g, 0.285 mmol) dissolved in 16 mL of EtOH, NaHSO3 (0.178 g, 1.7 mmol) dissolved 
in 4 mL DI H2O was added all at once.  The pH was adjusted to about 8 with 5 % NaOH and the 
mixture was refluxed until 23a had disappeared and a spot appeared on the baseline on TLC (6:1 
CHCl3/MeOH).  The solution was cooled in an ice bath and concentrated HCl was added until 
the pH was about 1, the solution was cooled further in the refrigerator overnight.  A pale yellow 
precipitate fell out of solution, which was vacuum filtered to yield 24a as a pale yellow solid 
(0.110 g, 77 %): mp 210-215 °C.  TLC (5:2 CHCl3/MeOH) Rf = 0.25.  1H NMR data: δ 9.96 (s, 
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1H), 9.89 (s, 1H), 8.14 (t, J = 6.2 Hz, 1H), 7.77 (t, J = 6.2 Hz, 1H), 7.22 (d, J = 1.2 Hz, 1H), 7.13 
(d, J = 1.2 Hz, 1H), 7.04 (d, J = 2.0 Hz, 1H), 6.87 (d, J = 1.2 Hz, 1H), 6.85 (d, J = 1.2 Hz, 1H), 
6.49 (d, J = 2.0 Hz, 1H), 6.40 (s, 1H), 3.81 (s, 3H), 3.78 (s, 3H), 0.65 (s, 3H).  13C NMR data: δ 
169.46, 168.83, 161.83, 158.84, 155.42, 136.46, 130.09, 127.125, 123.07, 122.89, 122.65, 
122.51, 118.59, 116.23, 113.32, 104.91, 104.39, 80.54, 48.00, 46.43, 43.42, 42.51, 42.20, 38.96, 
38.23, 37.22, 36.54, 36.50, 34.59, 33.23, 32.82, 30.32, 29.68, 29.64, 28.05, 27.52, 26.96, 25.62, 
22.74, 11.77. 
 3-{[5-({[5-({[3-({6-[(7ξ,8ξ,9ξ,14ξ,17ξ)-3,17-dihydroxyestra-1,3,5(10)-trien-7-
yl]hexyl}amino)-3-oxopropyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]amino}carbonyl)-
1-methyl-1H-pyrrol-3-yl]amino}-3-oxopropane-1-sulfonic acid (24b).  Compound 24b was 
synthesized similar to the procedure described above for 24a using 0.300 g (0.350 mmol) of 23b 
dissolved in 8 mL of EtOH, and 0.146 g (1.4 mmol) of NaHSO3 in 2 mL H2O. To yield a pale 
yellow precipitate that fell out of solution, which was vacuum filtered to yield 24b as a pale 
yellow solid (0.238 g, 82 %): mp 208.212 °C.  TLC (5:2 CHCl3/MeOH) Rf = 0.23.  1H NMR 
data: δ 9.96 (s, 1H), 9.84 (s, 1H), 7.97 (t, J = 6.4 Hz, 1H), 7.83 (t, J = 6.4 Hz, 1H), 7.18 (d, J = 
1.2 Hz, 1H), 7.13 (d, J = 1.2 Hz, 1H), 7.07 (d, J = 2.2 Hz, 1H), 6.83 (d, J= 1.2 Hz, 1H), 6.78 (d, J 
= 1.2 Hz, 1H), 6.49 (d, J = 2.2 Hz, 1H), 6.40 (s, 1H), 3.79 (s, 3H), 3.77 (s, 3H), 0.64 (s, 3H).  13C 
NMR data: δ 170.71, 168.90, 161.67, 158.80, 155.41, 136.49, 130.11, 127.13, 123.20, 123.08, 
122.53, 118.55, 118.32, 116.24, 113.31, 104.34, 80.55, 48.03, 46.43, 43.42, 42.20, 38.87, 38.22, 
37.22, 36.53, 36.41, 35.97, 34.60, 33.20, 32.91, 30.33, 29.60, 28.02, 27.53, 27.02, 25.59, 22.74. 
 3-{[5-({[5-({[4-({6-[(7ξ,8ξ,9ξ,14ξ,17ξ)-3,17-dihydroxyestra-1,3,5(10)-trien-7-
yl]hexyl}amino)-4-oxobutyl]amino}carbonyl)-1-methyl-1H-pyrrol-3-yl]amino}carbonyl)-1-
methyl-1H-pyrrol-3-yl]amino}-3-oxopropane-1-sulfonic acid (24c).  Compound 24c was 
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synthesized similar to the procedure described above for 24a using 0.750 g (0.862 mmol) of 23c 
dissolved in 24 mL of EtOH, and 0.146 g (5.1 mmol) of NaHSO3 in 6 mL H2O. To yield a pale 
yellow precipitate that fell out of solution, which was vacuum filtered to yield 24c as a pale 
yellow solid (0.350 g, 80 %): mp 197-202 °C.  TLC (5:2 CHCl3/MeOH) Rf = 0.21.  1H NMR 
data: δ 9.97 (s, 1H), 9.85 (s, 1H), 8.00 (t, J = 6.4 Hz, 1H), 7.80 (t, J = 6.4 Hz, 1H), 7.16 (d, J = 
1.2 Hz, 1H), 7.13 (d, J = 1.2 Hz, 1H), 7.03 (d, J = 2.0 Hz, 1H), 6.83 (d, J = 1.2 Hz, 2H), 6.49 (d, J 
= 2.0 Hz, 1H), 6.40 (s, 1H), 3.79 (s, 3H), 3.77 (s, 3H), 0.64 (s, 3H).  13C NMR data: δ 172.13, 
168.74, 161.71, 158.81, 155.42, 136.45, 130.08, 127.10, 123.35, 123.10, 122.50, 118.55, 188.23, 
116.23, 113.31, 104.58, 104.33, 80.55, 49.05, 47.99, 46.43, 43.41, 42.20, 40.99, 38.90, 38.65, 
38.22, 37.21, 36.54, 36.40, 34.59, 33.53, 33.20, 32.73, 30.32, 29.62, 28.02, 27.52, 27.01, 26.12, 
25.58, 22.74, 11.76. 
1-methyl-4-{[(1-methyl-4-nitro-1H-pyrrol-2-yl)carbonyl]amino}-N-propyl-1H-
pyrrole-2-carboxamide (25).  To a solution of proplyamine (0.01 mL, 0.137 mmol), EDCI 
(0.041 g, 1.5 eq), DMAP (0.033 g, 2.5 eq), HOBt (0.63 g, 3 eq.), and CuCl2 (0.002 g, 0.1 eq.) in 
dry DMF (5 mL), the carboxylic acid (18) (0.050 g, 0.137 mmol) was added.  The solution was 
allowed to sir under Ar until 18 had disappeared as indicated by TLC (EtOAc).  The solution was 
diluted with 60 mL EtOAc and washed with H2O (2x, 20 mL), saturated NaHCO3( 2x, 50 mL), 
and 1M HCl (2x, 50 mL).  The organic layer was dried over MgSO4 and the resulting yellow 
solution was concentrated by rotary evaporation to give pure 25 (0.36 g, 65 %): mp 220-225 °C.  
TLC (EtOAc) Rf = 0.41.  1H NMR data: δ 10.23 (s, 1H), 8.18 (d, J = 2.0 Hz, 1H), 8.05 (t, J = 5.0 
Hz, 1H), 7.58 (d, J = 2.0 Hz, 1H), 7.20 (d, J = 1.6 Hz, 1H), 6.84 (d, J = 2.0 Hz, 1H), 3.95 (s, 3H), 
3.80 (s, 3H), 3.13 (q, J = 7.2, 5.8 Hz, 2H), 1.50 (p, J = 7.8, 6.2, 5.2 Hz, 2H), 0.88 (t, J = 7.4 Hz, 
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3H).  13C NMR data: δ 161.54, 157.28, 134.23, 128.67, 126.76, 123.81, 121.74, 118.31, 107.99, 
104.35, 37.94, 36.46, 23.03, 11.90. 
ethyl 4-({[4-({[4-(methylsulfonyl)-1-methyl-1H-pyrrol-2-yl]carbonyl}amino)-1-
methyl-1H-pyrrol-2-yl]carbonyl}amino)butanoate (26) Compound 20c (0.100 g, 0.266 mmol) 
was dissolved in 15 mL absolute ethanol and 250 mg Pd/C was added in a parr jar.  The mixture 
was shaken under pressurized hydrogen (75 psi) until 20c had disappeared as indicated by TLC 
(EtOAc).  The Pd/C was filtered through celite, and the solution was rotary evaporated and the 
residue was kept under vacuum overnight.  The 3-(methylsulfonyl) propanoic acid (0.048 g, 
0.319 mmol) was dissolved in 10 mL anhydrous DMF along with, EDCI (0.078 g, 1.5 eq.) 
DMAP (0.081 g, 2.5 eq.), HOBT (0.121 g, 3 eq.), CuCl2 (0.004 g, 0.1 eq.), After stirring for 30 
min. the reduced compound 20c was then added, and the solution was allowed to stir at room 
temperature over a period of three days until the disappearance of starting material as indicated 
by TLC (6:1 CHCl3/MeOH).  The solution was diluted with 100 mL DCM and the organic 
solution was extracted with H2O (2x, 100mL), saturated NaHCO3 (2x, 150 mL), and 1 M HCl 
(2x, 150 mL).  The organic layer was then dried over MgSO4.  The resulting solution was rotary 
evaporated until dry to yield the product, 26 as an orange solid (0.101 g, 74%): mp °C. TLC (6:1 
CHCl3/MeOH) Rf = 0.64.  1H NMR data: δ 10.06 (s, 1H), 9.87 (s, 1H), 8.03 (t, J = 6.2 Hz, 1H), 
7.17 (d, J = 2.0, 1H), 7.16 (d, J = 1.6 Hz, 1H), 6.86 (d, J = 2.0 Hz, 1H), 6.85 (d, J = 2.0 Hz, 1H), 
4.07 (q, J = 7.2, 6.8 Hz, 2H), 3.82 (s, 3H), 3.79 (s, 3H), 3.42 (t, J = 7.2 Hz, 2H), 3.18 (q, J = 7.2, 
6.4 Hz, 2H), 3.01 (s, 3H), 2.51 (t, J = 7.0 Hz, 2H), 1.17 (t, J = 7.0 Hz, 2H), 1.19 (t, J = 7.0 Hz, 
3H).  13C NMR data: δ 173.17, 166.53, 161.74, 158.74, 123.32, 123.28, 122.45, 122.13, 118.61, 
118.30, 104.63, 104.27, 60.21, 50.20, 38.15, 36.61, 36.40, 31.50, 28.65, 25.16, 14.58. 
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CHAPTER 8:  RESULTS AND DISCUSSION 
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This thesis describes the efforts to synthesize the bifunctional compounds shown below 
in Figure 8.1.  The main goal was to synthesize compounds that could potentially produce N3-
methyladenine adducts in estrogen receptor positive cells.  The design of these compounds 
utilized the properties of both portions of the molecule; the ability to bind to the ER, and to 
produce N3-methyladenine adducts.   
Figure 8.2 illustrates the synthetic strategy that was developed in order to synthesize 
these compounds in a modular fashion. This is achieved by synthesizing the cell-targeting ligand 
and the DNA-recognizing ligand separately. The two would then be combined by a suitable 
linker.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 106
HO
OH
N H
N
N
H
N R
N
H
O
O
NH
O
O
S OO
H3CO
 
Figure 8.1:  Structure of bifunctional compounds capable of producing N3- 
                    methyladenine adducts in ER positive cells. 
 
 
 
 
 
Figure 8.2: Synthetic strategy used to prepare compounds that can target estrogen 
                          receptor positive cells causing N3-methyladenine adducts in those cells 
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The linker that connects these two segments must be modified in such a way that 
estradiol would still be able to bind to the ER, and the DNA-methylating portion would still be 
able to produce N3-methyladenine adducts.  Three compounds containing the DNA-recognizing 
functionality and the cell-targeting functionality were synthesized with varying linker lengths, 
methyl, ethyl or propyl.    Having synthesized compound 24, the final step that remains is the 
addition of the reactive methyl sulfonate to form 27.   
The cell-targeting unit was synthesized following published procedures, many of which 
were air and moisture sensitive.  Compound 9 was synthesized in a 6% yield, with low reported 
yields.  Occasionally, during the workup of the final step of this sequence, the protecting group 
was removed from the phenolic OH.  It was determined that this was of no consequence to 
subsequent reactions.  Due to time and resource expense, compound 9 was commercially 
obtained from Quality Chemical Laboratories.   
The synthesis of the DNA-methylating unit was synthesized from N-methyl pyrrole 
following published procedures with minor modifications.  Compounds 22a, 22b, and 22c were 
synthesized in 32%, 43%, and 32% yields respectively.   
Initially, attempts were made to synthesize the compound shown below in Figure 8.3, 
which would allow for the addition of linkers at a later stage of the synthesis.  However, as 
Scheme 8.1 illustrates, it was proposed that Michael addition across the alkene had occurred in 
addition to hydrolysis of the linker ester, so this methodology was abandoned.   
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Figure 8.3:  compound to be synthesized for easy addition of linkers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 109
TEA
EtOAc
N
O2N
CCl3
O
N
CCl3
O
12
N
11
1) trichloro acetyl
chloirde
2) K2CO3
DCM
HNO3
Acetic Anhydride
81%93%
N
H3N
OCH3
O
N
NH
N
O CH3
O
NO2
O
Cl
O
DIEA
THF
N HN
N
OCH3
O
NH
O
O
N HN
N
OH
O
NH
O
O1) NaOH/H2O
2) HCl
EtOH
17
2)
1) Pd/C
EtOH
N HN
N
OH
O
NH
O
O
HO
Michael
Addition
???
blue - expected product
red - michael addition product
 
 
Scheme 8.1 
 
The new methodology employed utilized the addition of the linker earlier in the 
synthesis; this did not pose a problem since the addition of the linker and reactions thereafter 
result in high yields.  The overall synthesis employed for these compounds is illustrated below in 
Scheme 8.2a, 8.2b, and 8.2c.   
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Scheme 8.3 illustrates the conversion of the sulfonic acid to the final methyl sulfonate. 
Several attempts to synthesized 27 were done using different methylating agents such as, 3-
methyl-p-tolyltriazene, trimethylorthoformate, trimethylorthoacetate, and iodomethane.   
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Scheme 8.3 
While these attempts were unsuccessful, other options exist.  For example, diazomethane, 
which has been reported in literature for methylating sulfonic acids, could be employed.  A 
potential complication with this method is the possibility of methylating the OH groups of 
estradiol.  Literature reports suggest that in order for phenolic or alcoholic OH groups to react 
under diazomethane conditions, a catalyst must be present.36-38 Therefore; this method should not 
result in the methylation of the OH groups of estradiol.  Another potential complication with this 
method involves the solubility of the molecules.  Diazomethane is prepared in either ether or 
DCM, both of which are non-polar, 24 is a polar compound that is readily soluble in methanol, 
not ether or DCM.  Methanol could be used, except that the desired methyl sulfonate is reactive, 
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and will methylate the methanol to form dimethyl ether.  This would eliminate methanol as a 
potential solvent.  A way to avoid this is to use trifluoro methanol, the fluorine renders the 
oxygen of methanol less nucleophillic, slowing the reaction of the methyl sulfonate with 
methanol.   
Once the final conversion to the methyl sulfonate is achieved, these compounds can be 
reacted with genomic DNA to see if N3-methyladenine is formed, and whether the length of the 
tether affects the compounds ability to methylate DNA.  Also, by obtaining the ER 
commercially, these compounds can be tested for their ability to bind to the ER.  Once 
compounds are identified that posses both of these qualities the compounds will be tested in ER 
positive and ER negative cells to see if there is selective cytotoxicity for cells over-expressing 
the estrogen receptor. 
 
 
 
 
 
. 
 
 
 
 
 
 
 
 115
REFERENCES 
1. Biello, D. Environmental DNA Damage May Drive Human Mutation. Scientific  
American.  May 2006. 
2. Engelward, B.P.; Allan, J. M.; Dreslin, A. J.; Kelly, J.D.; Gold, B.; Samson, L.D. 3-
Methyladenine DNA Lesions Induce Chromosome Abberations, Cell Cycle Delay, and 
Apoptosis.  J. Biol Chem.  1998, 273, 5412-5418. 
3. The Anticancer Drugs (1994) 2nd ed. (Pratt, W.B.; Ruddon, R. W.; Ensminger, W.D.; 
Maybaum, J., Eds) Oxford Press, New York. 
4. Hurley L.H. DNA and its Associated Processes as Targets for Cancer Therapy Nature 
Reviews, Cancer.  2002, 2, 188-200. 
5. Elsner, M.; Guldbakke, B.; Tiedge, M.; Munday, R.; Lenzen, S.  Relative importance of 
transport and alkylation for pancreatic beta-cell toxicity of streptozotocin.  Diabetologia 
(2000), 43(12), 1528-1533. 
6. Lemieux, P.; Fugua, S. The Role of the Estrogen Receptor in Tumor Progression J. 
Steriod Biochem. Molec. Biol. 1996, 56, 87-91. 
7. Fronza, Gilberto; Gold, Barry.  The Biological Effects of N3-Methyladenine.  Journal 
of Cellular Biochemistry.  2004, 91, 250-257 
8. Lawley, P.D.  Carcinogenesis by Alkylating Agents.  Chemical Carcinogens.  1984, 1, 
325-484, American Chemical Society, Washington, DC. 
9. Tentori, L; Olindo F.; Fossile E.; Muzi A.; Vergati M.; Portarena I.; Amici C.; Gold B.; 
Graziani G.  N3-Methyladenine Induces Eary Poly(ADP-Ribosylation), Reduction of 
Nuclear Factor-κB DNA Binding Ability, and Nuclear Up-Regulation of Telomerase 
Activity.  Molecular Pharmacology.  2004, 67, 572-581 
 116
10. Beranek, D.T.; Weis, C.C.; Swenson, D.H.  A Comprehensive Quantitative Analysis of 
Methylated and Ethylated DNA Using HPLC. Carcinogenesis.  1980, 1, 595-605 
11. Shah, Dharine; Gold Barry.  Evidence in Escherichia Coli that aN3-Methyladenine 
Lesions and Cytotoxicity Induced by a Minor Groove Binding Methyl Sulfonate Ester 
Can Be Modulated In Vivo by Netropsion. Biochemistry.  2003, 42, 12610-12626. 
12. Monti, P; Iannone, R; Campomenosi, P; Ciribilli, Y; Varadarajan, S; Sha, D; Menichini, 
P; Gold, B; Fronza, G.  Nucleotide Excision Repair Defect Influences Lethality and 
Mutagenicity Induced by Me-Lex, a SequencepSelective N3-Adenine Methylating Agent 
in the Absence of Base Excision Repair.  Biochemistry.  2004, 43, 5592-5599. 
13. Varadarajan, Sridhar; Shah, Dharini; Dande, Prasad; Settles, Samuel; Chen, Fa-Xian; 
Fronza, Gilberto; Gold, Barry.  DNA Damage and Cytotoxicity Induced by Minor 
Groove Binding Methyl Sulfonate Esters.  Biochemistry.  2003, 42, 14318-14327. 
14. Engleward, B.P.; Allan, J.M.; Dreslin, A.J.; Kelly, J.D.; Gold, B.; Samson, L.D.  3-
Methyladenine DNA Lesions Induce Chromosome Abberations, Cell Cycle Delay, and 
Apoptosis. J. Biol. Chem.  1998, 273, 5412-5418. 
15. Zhang, Yi; Chen, Fa-Xian; Mehta, Pratibha; Gold, Barry.  Groove-and Sequence-
Selective Alkylation of DNA by Sulfonate Esters Tethered to Lexitropsins. 
Biochemistry. 1993, 32, 7954-7965. 
16. Parker, M.G.; Arbuckle, N.; Dauvois, S.; Daniellian, P.; White, R.  Structure and 
Function of the Estrogen Receptor. Imperial Cancer Research Fund Molecular 
Endocrinology Laboratory.   Lincolns Inn Fields. 119-126 
 117
17. Kumar, Vijay; Green, Stephen; Stack, Gary; Berry, Meera; Jin, Jia-Rui; Chambon, Pierre.  
Functional Domains of the Human Estrogen Receptor Cellular Biology.  1987, 51, 941-
951. 
18. Roy, Urmi; Luck, Linda. Molecular Modeling of Estrogen Receptor Using Molecular 
Operating Environment  Biochemistry and Molecular Biology Education.  2007, 35, 
238-243. 
19. Swamy, N.; Jame, D.A.; Mohr, S.C.; Hanson, R.N.; Ray, R. An Estradiol-Porphyrin 
Conjugate Selectivity Localizes Into Estrogen Receptor-Positive Breast Cancer Cells 
Bioorg. Med. Chem.  2002, 10, 3232-3243. 
20. Murphy, L.C.; Dotzlaw, H.; Leygue, E.; Coutts, A.; Watson, P. The Pathophysiological 
Role of Estrogen Receptor Variants in Human Breast Cancer.  J. Steroid Biochem. 
Molec. Biol.  1998, 65, 175-180. 
21. Kassis, Judy; Gorski, Jack.  On the Mechanism of Estrogen Receptor Replenishment: 
Recycling, Resynthesis and/or processing Molecular and Cellular Biochemistry.  1983, 
52, 27-36. 
22. Flototto, T.; Niederacher, D.; Hohmann, D.; Heimerzheim, T.; Dall, P.; Djahansouzi, S.; 
Bender, H.G.; Hanstein, B.  Molecular Mechanism of Estrogen Receptor (ER)α-specific, 
Estradiol-dependent Expression of the Progesterone Receptor (PR) B-isoform. Steroid 
Biochemistry. 2004, 88, 131-142. 
23. Essigmann, J. M.; Rink, S. M.; Park, H.; Croy, R. G. Design of DNA Damaging Agents 
That Hijack Transcription Factors And Block DNA Repair Bio. Reac. Inter. VI. 2001, 
301-313. 
 118
24.   Kuduk, S. D.; Zheng, F. F.; Sepp-Lorenzino, L.; Rosen, N.; Danishefsky, S. J. Synthesis 
and Evaluation of Geldanamycin-Estradiol Hybrids Bioorg. Med. Chem. Let. 1999, 9, 
1233-1238. 
25. Mitra, K.; Marquis, J. C.; Hillier, S. M.; Rye, P. T.; Zayas, B.; Essigmann, J. M.; Croy, R. 
G. A Rationally Designed Genotoxin that Selectively Destroys Estrogen Receptor-
Positive Breast Cancer Cells J. Am. Chem. Soc. 2002, 124, 1862-1863. 
26. Spera, D.; Cabrera, G.; Fiaschi, R.; Carlson, K. E.; Katzenellenbogen, J. A.; Napolitano, 
E. Estradiol derivatives bearing sulfur-containing substituents at the 11β or 7α positions: 
versatile reagents for the preparation of estrogen conjugates Bioorg.Med.Chem. 2004, 
12, 4393-4401. 
27.   Tedasco, R.; fiaschi, R.; Napolitano, E. 6-Oxoestradiol from Estradiols: Exploiting Site 
Selective Metalation of Aralkyl Systems with Superbases Synthesis. 1995, 1493-1495. 
28.   Skaddan, M. B.; Wust, F. R.; Katzenellenbogen, J. A. Synthesis and Binding 
Affinitiesof Novel Re-Containing 7α-Substituted Estradiol Complexes: Models for Breast 
Cancer Imaging Agents J. Org. Chem. 1999, 64, 8108-8121. 
29.   Spino, C.; Barriaylt, N. Radical Cyclization of Polyenes Initiated by Attack of Trialkyltin or Germanium Radical 
on an Ynone J. Org. Chem. 1999, 64, 5292-5298. 
30. Xia, Juhauna; Yuan, Gu; Huang, Weiqiang; Chan, Albert; Lee, Daniel.  A Convenient 
Method for the Synthesis of DNA-Recognizing Polyamides in Solution.  J. Org. Chem. 
2000, 65, 5506-5513. 
31. Padmapriya, A.A.; Just, G.; Lewis, N.G.  A new method for the Esterification of 
Sulfonic Acids.  Synthetic Communications. 1985, 15, 1057-1062. 
 119
32. Trujillo, John; Gopalan, Aravamudan.  Facile Esterification of Sulfonic Acids and 
Carboxylic Acids with Triethylorthoacetate.  Tetrahedron. 1993, 34, 7355-7358.  
33. Tomonori, Yoshino; Hides,Togo.  Facile Preparation of Polymer Supported Methyl 
Sulfonate and its Recyclable Use for Methylation of Carboxylic Acids and Amines. 
Synlett.  2005, 3, 517-519. 
34. Pounds, Scot. Synthesis and Application of Isotopically labeled Compounds.  
Proceedings of the International Symposium 8th, Boston, MA; United States, June 1-5, 
2005, 469-472. 
35. Smith, Michael B.; March, Jerry.  Methylation of Alcohols with Diazomethane. 
Marchs Advanced Organic Chemistry, Reactions, Mechanisms and Structure 5th edition, 
pp. 479.  
36. Haruo, Ogauce; Toshikazu, Hagiwara; Teiji, Chihara; Shousuke, Teratani; Kazuo Taya.  
Methylation of Alcohols and Phenols absorbed on Silica Gel with Diazomethane.  The 
Chemical Society of Japan.  1987, 60, 627-629. 
37. Newman, M.; Marjorie, Caserio; Roberts, John; Johnson, William.  Methylation of 
Alcohols with Diazomethane.  Tetrahedron.  1959, 6, 36-47. 
38. Glastrup, Jens.  Diazomethane Preparation for Gas Chromatographic Analysis.  
Journal of Chromatography.  1998, 827, 133-136. 
39. Grayson, Ian.  Water-soluble carbodiimide  an efficient agent for synthesis.  
Pharmaceutical Intermediates. 2000, 86-88. 
 
 
 
 120
40. Miyazawa, Toshifumi; Otomatsu, Toshihiko; Fukui, Yoshimasa; Yamada, Takashi; 
Kuwata, Shigeru.  Racemization-free and Efficient Peptide Synthesis by the 
Carbodiimide Methods using 1-Hydroxybenzotriazole and Copper (II) Chloride 
simultaneously as Additives.  J. Chem. Soc., Chem. Commun.  1988, 419-420. 
41. Hofmann, J. E.; Wallace, T. J.; Argabright, P. A.; Schriesheim, A. Production of olefins 
from aliphatic sulfones and sulfoxides. Chemistry & Industry (London, United Kingdom) 
1963, (30), 1243-4. 
42. Truce W, Knospe R. The Preparation of beta-Keto Sulfones by the Claisen 
Condensation.Deparment of Chemistry Purdue University. 1955, 77, 5063-5067. 
43. Scott L. Gibson, Russell Hilf, David J. Donnelly, Michael R. Detty, Analogues of 
tetramethylrosamine as transport molecules for and inhibitors of P-glycoprotein-mediated 
multidrug resistance. Bioorganic & Medicinal Chemistry.  2004, 12 (17), 4625-4631. 
44. Fuhrhop, Jrgen-Hinrich; David, Has-Hermann; Mathiew, Joachim; Liman, Wulrich; 
Winter, Hans-Jorg; Boekema, Egbert.  Bolaamphiphiles and Monolayer Lipid 
Membrandes Made from 1,6,19,24-Tetraoza-3,21-cyclohexatriazontadiene-2,5,20,23-
tetrone. J. Am. Chem. Soc.  1986, 108, 1785-1791. 
45. Peter, K.; Vollhardt, C.; Schore, N.E.; Organic Chemistry Structure and Function, Third 
Edition.  1998, 805-808. 
 
 
 
 
 
 
 121
APPENDIX 
 
Appendix A.  Number, structure and yields of synthesized compounds. 
 
Number Compound Yield 
1 THPO
OTHP
C28H40O4
Mol. Wt.: 440.61 
 
 
85% 
2 THPO
OTHP
OH
C28H40O5
Mol. Wt.: 456.61 
 
 
74% 
3 THPO
OTHP
O
C28H38O5
Mol. Wt.: 454.60  
 
 
78% 
4 THPO
OTHP
O
C34H48O5
Mol. Wt.: 536.74  
 
 
43% 
5 HO
OH
C24H34O2
Mol. Wt.: 354.53  
 
 
81% 
6 TBSO
OTBS
C36H62O2Si2
Mol. Wt.: 583.05  
 
 
78% 
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7 TBSO
OTBSHO
C36H64O3Si2
Mol. Wt.: 601.06  
 
 
74% 
8 TBSO
OTBSN
O
O
C44H67NO4Si2
Mol. Wt.: 730.18  
 
 
87% 
9 TBSO
OHH2N
C30H51NO2Si
Mol. Wt.: 485.82  
 
 
80% 
10 
OCH3
HO
C19H26O2
Mol. Wt.: 286.41 
 
 
89% 
11 
N
CCl3
O
C7H6Cl3NO
Mol. Wt.: 226.49 
 
 
93% 
12 
N
O2N
CCl3
O
C7H5Cl3N2O3
Mol. Wt.: 271.48 
 
 
81% 
13 
N
O2N
OH
O
C6H6N2O4
Mol. Wt.: 170.12  
 
 
 
98% 
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14 
N
O2N
OCH2CH3
O
C8H10N2O4
Mol. Wt.: 198.18  
 
 
 
80% 
15a 
 
N
O2N
H
N
O
OCH2CH3
O
C10H13N3O5
Mol. Wt.: 255.23  
 
 
 
83% 
15b 
N
O2N
H
N
O
OCH2CH3
O
C11H15N3O5
Mol. Wt.: 269.25  
 
 
88% 
15c 
N
O2N
H
N
O
OCH2CH3
O
C12H17N3O5
Mol. Wt.: 283.28  
 
 
81% 
16 
N
O2N
O
H
N
OH
O
C10H13N3O5
Mol. Wt.: 255.23  
 
 
98% 
17 
N
H
N
O
N
OCH3
O
O2N
C13H14N4O5
Mol. Wt.: 306.27  
 
 
92% 
18 
N
H
N
O
OH
N
O2N
O
C12H12N4O5
Mol. Wt.: 292.25  
 
 
99% 
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19 
N
H
N
O
OCH2CH3
N
O2N
O
C14H16N4O5
Mol. Wt.: 320.3  
 
 
 
68% 
20a 
N
H
N
O
HNN
O2N
O
O
OEt
C16H19N5O6
Mol. Wt.: 377.35  
 
 
 
73% 
20b 
N
H
N
O
HNN
O2N
O
O
OEt
C17H21N5O6
Mol. Wt.: 391.38  
 
 
81% 
20c 
N
H
N
O
HN
N
O2N
O
O
OEt
C18H23N5O6
Mol. Wt.: 405.41  
 
 
 
71% 
21a 
N
H
N
O
HNN
NH
O
O
OEt
O
C19H23N5O5
Mol. Wt.: 401.42  
 
 
 
 
86% 
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21b 
N
H
N
O
HNN
NH
O
O
OEt
O
C20H25N5O5
Mol. Wt.: 415.44  
 
 
 
 
89% 
21c 
N
H
N
O
HN
N
NH
O
O
OEt
O
C21H27N5O5
Mol. Wt.: 429.47  
 
 
 
87% 
22a 
N
H
N
O
HNN
NH
O
O
OH
O
C17H19N5O5
Mol. Wt.: 373.36  
 
 
 
85% 
22b 
N
H
N
O
HNN
NH
O
O
OH
O
C18H21N5O5
Mol. Wt.: 387.39  
 
 
 
88% 
22c 
N
H
N
O
HN
N
NH
O
O
OH
O
C19H23N5O5
Mol. Wt.: 401.42  
 
 
 
 
86% 
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23a 
N
NH
O
H
N
N
NH
O
O
N
H
O
TBSO
OH
C47H68N6O6Si

Mol. Wt.: 841.17  
 
 
 
 
 
74% 
23b 
N
H
N
O
HN
N
NH
O
O
N
H
O
TBSO
OH
C48H70N6O6Si

Mol. Wt.: 855.19  
 
 
 
76% 
23c 
N
NH
O
H
N
N
NH
O
O
N
H
O
TBSO
OH
C49H72N6O6Si

Mol. Wt.: 869.22  
 
 
 
 
72% 
24a 
N
NH
O
H
N
N
NH
O
O
N
H
HO
OH
S
O
O
O
HO
C41H56N6O9S
Mol. Wt.: 808.98  
 
 
 
 
 
77% 
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24b 
N
HN O
HN
N
H
N
O
O
N
H
HO
OH
S
O
O
O
HO
C42H58N6O9S
Mol. Wt.: 823.01  
 
 
 
 
82% 
24c 
N
NH
O
H
N
N
NH
O
O
N
H
HO
OH
S
O
O
O
HO
C43H60N6O9S
Mol. Wt.: 837.04  
 
 
 
 
80% 
25 
N
H
N
O
N
HN
O
O2N
C15H19N5O4
Mol. Wt.: 333.34  
 
 
 
65 % 
26 
N
H
N
N
O
HN
O
OCH2CH3
ONH
O
S
O
O
H3C
C22H31N5O7S
Mol. Wt.: 509.58  
 
 
 
 
 
74% 
27a 
N
NH
O
H
N
N
NH
O O
N
H
HO
OH
S
O
O
O
H3CO
Chemical Formula: C42H58N6O9S
Molecular Weight: 823.01  
 
Not yet 
synthesized 
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27b 
N
H
N
O
H
N
N
NH
O
O
HN
HO
OH
S
O
O
OH3CO
Chemical Formula: C43H60N6O9S
Molecular Weight: 837.04  
Not yet 
synthesized 
27c 
N
NH
O
H
N
N
NH
O O
N
H
HO
OH
S
O
O
O
H3CO
Chemical Formula: C129H180N18O25S3
Molecular Weight: 2479.11  
Not yet 
synthesized 
28a 
N
NH
O
H
N
N
NH
O O
N
H
HO
OH
S
O
O
O
H3C
Chemical Formula: C42H58N6O8S
Molecular Weight: 807.01  
Not yet 
synthesized 
28b 
N
H
N
O
H
N
N
NH
O
O
HN
HO
OH
S
O
O
OH3C
Chemical Formula: C43H60N6O8S
Molecular Weight: 821.04  
Not yet 
synthesized 
28c 
N
NH
O
H
N
N
NH
O O
N
H
HO
OH
S
O
O
O
H3C
Chemical Formula: C129H180N18O24S3
Molecular Weight: 2463.11  
Not yet 
synthesized 
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Appendix B.  List of Abbreviations 
 
3-MeA  3-methyladenine 
3-MeG  3-methylguanine 
6-MeG  6-methylguanine 
A  adenine 
A/T  adenine-thymine 
C-cytosine 
CDCl3 - Deuterated Chloroform 
DCM  dichloromethane 
DIEA  diisopropylethylamine 
DNA  deoxyribose nucleic acid 
DMAP  4-dimethylaminopyridine 
DMF  dimethylformamide 
DMSO  methyl sulfoxide 
EDCI  1-(3-dimethylaminopropyl)-3-ethylcarbodiimidehydrochloride 
ER  estrogen receptor 
EtOAc  ethyl acetate 
EtOH  ethanol 
G  guanine 
HCl  hydrochloric acid 
HOBT  hydroxybenotriazole 
KOt-Bu  potassium tert-butoxide 
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Me-Lex  methyl 3-(1-methyl-5-(1-methyl-5-(propylcarbmoyl)-1H-pyrrol-3- 
     ylcarbamoyl)-1H-pyrrol-3-ylamino)-3-oxopropane-1-sulfonate  
MeOH  methanol 
mp  melting point 
NaCl  sodium chloride 
NaOH  sodium hydroxide 
NMR  muclear magnetic resonance 
Pd/C  palladium on carbon 
Rf  retention factor 
TBS  tertbutyl dimethylsilyl 
TEA  triethylamine 
THF  tetrahydrofuran 
THP - tetrahydropyranyl 
TLC  thin layer chromatography 
T  thymine 
UV  ultra violet 
 
 
 
